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ABSTRACT
Alshahrani, Saeed. M.S., Department of Pharmacology and Toxicology, Wright State
University, Boonshoft School of Medicine 2012. Role of NKCC co-transporters in
insulin secretion.

The maintenance of high intracellular chloride concentration ([Cl–]i) in insulinsecreting pancreatic β-cells plays an important role in glucose-induced depolarization and
insulin secretion. Glucose promotes the electrogenic efflux of Cl– contributing to β-cell's
electrical and secretory activity. The solute carrier family 12 group A member 1
(Slc12a1) and 2 (Slc12a2) encode several splice variants of the kidney-specific and the
ubiquitous isoforms, respectively, of bumetanide (BTD)-sensitive Na+-dependent K+2Cl–
co-transporters. The Slc12a2 co-transporter, also known as NKCC1, is involved in the
maintenance of a high [Cl–]i in β-cells and its pharmacological inhibition impairs insulin
secretion in response to glucose in vivo and in vitro. The present study shows that mice
lacking both functional alleles of the Slc12a2 gene (NKCC1 KO) have better fasting
glycaemia and improved glucose tolerance when compared to wild-type mice (NKCC1
WT). These observations correlated with increased insulin secretion in response to
glucose in vivo and in vitro and with increased β-cell mass. Moreover, administration of
BTD to NKCC1 KO mice worsened their glucose tolerance. This effect of BTD in vivo
correlated with a direct inhibition of insulin secretion by BTD from islets lacking
functional Slc12a2 genes, therefore suggesting the presence of a BTD-sensitive
mechanism involved in insulin secretion, which is different from Slc12a2. Molecular
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expression analysis demonstrates that β-cells express a specific splice variant of the
kidney-specific BTD-sensitive Slc12a1 gene i.e., NKCC2A. Altogether, our results
provide for the first time evidence for a functional role of this co-transporter on insulin
secretion.

Conclusions: 1) Functional alleles of the Slc12a2 gene are not necessary for insulin
secretion. 2) Bumetanide impairs insulin secretion and glucose homeostasis in vivo. 3)
Bumetanide impairs insulin secretion by a direct effect on insulin secreting β-cells. 4)
Pancreatic β-cells express specific splice variants of Slc12a2 and Slc12a1 i.e., NKCC1a
and NKCC2A.
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1- INTRODUCTION
Diabetes Mellitus
Diabetes mellitus is a poly-endocrine and metabolic disorder characterized by
chronic hyperglycemia along with disturbances of carbohydrate, fat and protein
metabolism (Ostenson 2001). This syndrome results from either defect in insulin
secretion or insulin action or both. According to the American Diabetes Association, 25.8
million children and adults in the United States are suffering from diabetes, meaning that
~8.3% of the population have diabetes (Zhang 2011). Worldwide, the total number of
individuals suffering from diabetes is projected to increase to 366 million in 2030. I fact,
the World Health Organization (WHO) has established recently that one out of 10 adults
worldwide

has

diabetes

(www.who.int/mediacentre/factsheets/fs312/en/index.html).

According to the International Diabetes Federation, diabetes mellitus in 2003 was the
fourth leading cause of death in most developed countries (www.idf.org/diabetesatlas).
Diabetes mellitus is categorized in three types. On one hand, type I diabetes (T1D),
also known as insulin dependent diabetes mellitus (IDDM) or juvenile onset diabetes, is a
relatively less common chronic metabolic disorder caused by β-cell destruction that leads
to absolute insulin deficiency. It requires insulin treatment constantly. On the other hand,
more than 85 % of all diabetic individuals are diagnosed with diabetes mellitus type II
(T2D). T2D is characterized by relative insulin deficiency due to low insulin secretion
rates or due to tissue resistance to the action of the hormone or a combination of both.
Characteristically, T2D ultimately endures due to dysfunction of the β-cells in the
pancreatic islets of Langerhans and due to a failure to provide enough insulin to supply
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tissue demands. The third type of diabetes, gestational diabetes mellitus, occurs during
pregnancy (DeFronzo 2004).
Currently, the only available treatment for T1D is administration of exogenous
insulin. Thus, T1D patients have to constantly monitor and observe their glucose levels
and inject insulin whenever required, always after meals. Lack of control can result in
either hypoglycemia, which can cause a coma (Katz, et al. 2012), or hyperglycemia,
which increases the risk of developing diabetic complications such as blindness, kidney
failure, amputations, and other complications (Cowie, et al. 1989; Icks, et al. 1997). On
the contrary, T2D is a more complex metabolic disorder usually found in combination
with obesity, impaired β-cell function (Kloppel, et al. 1985), increased endogenous
hepatic glucose output and insulin resistance in target tissues (Kolterman, et al. 1981;
Leahy 2005). Although the relative contribution and interaction of all of these defects in
the pathogenesis of T2D remains to be clarified (Cerasi 1995), therapeutic options are
aimed at improving β-cell or tissue sensitivity to glucose or insulin (Gerich 2002b).
Therefore, studying and elucidating the mechanisms involved in insulin secretion is of
capital relevance at the time of taking new therapeutic avenues to improve β-cell
function.

Synthesis and function of insulin
Insulin secretion from β-cells, a major part of islets of Langerhans, involves the
intimate dialogue between several external and internal signals. Thus, neurotransmitters,
hormones, nutrients, and drugs all stimulate or reduce insulin release (Ashcroft and
Rorsman 2012). Most of our knowledge regarding the molecular and functional
2

mechanisms involved in insulin secretion in response to glucose comes from in vivo and
in vitro experiments performed during the last 50 years [(Chou and Ipp 1990; Porksen, et
al. 2002; Smith, et al. 1990; Sturis, et al. 1994) and references therein]. Insulin is the only
hypoglycemic hormone of the organism (Rorsman, et al. 2000). Therefore, secretion of
insulin prevents hyperglycemia. Indeed, insulin reduces glycaemia by promoting glucose
uptake in tissues like adipose and muscle tissue, increasing glycogen synthesis and
inhibiting glucose release from glycogen storages, a process known as gluconeogenesis
(Jensen and Richter 2012).
Insulin is synthesized in the rough endoplasmic reticulum (ER) of β-cells as prepro-insulin, a 110 amino acid polypeptide product of the translation of the insulin gene.
Pre-pro-insulin is converted to pro-insulin by the action proteases. These proteases cleave
the signal peptide to generate pro-insulin, which begins to be packaged in the trans‐Golgi
network and sorted into immature secretory granules (Fig. 1). The ATP‐dependent H+
pump acidifies these immature granules and pro-insulin undergoes proteolytic cleavage
resulting the formation of mature insulin and C‐peptide in equal molar quantities. During
maturation of granules, insulin concentrates and crystallizes with Zn2+ and Ca2+ ions to
form the characteristic dense‐core granules of β-cells (Chausmer 1998). These mature
insulin-containing granules constitute two functionally different insulin pools, one that is
composed by granules that are readily releasable and another that is considered a reserved
pool [reviewed in (Hou, et al. 2009)]. These two different insulin-containing granule
populations are thought to be responsible for the biphasic nature of insulin release (Hou
et al. 2009). Indeed, the granules close to or associated with the plasma membrane are the
ones that are subjected to acute Ca2+‐dependent release, accounting for first phase insulin
3

secretion (see bellow). On the contrary, the second phase of insulin secretion requires
trafficking of reserved granules to the plasma membrane plus de novo insulin
biosynthesis (Hao, et al. 2005; Hou et al. 2009; Rorsman and Renstrom 2003).

!

Figure 1: Insulin biosynthesis. Pre-pro-insulin is synthesized
from the insulin gene and directed into the endoplasmic reticulum
by the signal sequence, where it folds into a suitable conformation
through disulfide bonds (SS). The signal sequence is then
removed, and pro-insulin is further processed in the Golgi
apparatus where the C-peptide is removed and mature insulin
produced.
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Phases of insulin secretion
Insulin secretion is stimulated primarily by glucose metabolism within the β-cell
(Rorsman and Renstrom 2003). Insulin is secreted in response to glucose in a welldefined fashion (Rorsman et al. 2000). Two phases of insulin secretion have been
identified. The first phase is a rapid or acute release of insulin stored in intracellular
granules of the β-cell located closely to the plasma membrane (Barg, et al. 2002;
Rorsman and Renstrom 2003). This phase is defined as the initial burst of insulin, which
is secreted in the first 5-10 min after β-cells exposure to increased glucose (Caumo and
Luzi 2004). The first-phase of insulin secretion is followed by the second-phase, which
involves de novo synthesis of insulin (Hou et al. 2009). Under normal physiological
conditions, this phase is sustained and lasts until normoglycaemia is reached (Caumo and
Luzi 2004) (Fig. 2). Impairment of first-phase insulin secretion is one of the earliest
manifestations of T2D (Gerich 2002a, b). Once established, impairment of the first phase
of insulin secretion negatively impacts glucose tolerance and carbohydrate metabolism,
and therefore T2D endures (Guillausseau, et al. 2008).
The second phase of insulin secretion is sustained and relatively slow when
compared to the first phase. It involves insulin stored in reserve granules and the
coordinated de novo biosynthesis of insulin. This phase of insulin secretion is frequently
impaired in both, patients with T2D and high-risk populations (Del Prato, et al. 2002;
Gerich 2002a, b). However, it is the impairment of the first phase of insulin secretion the
necessary defect in all conditions of impaired glucose regulation (Del Prato et al. 2002).

5
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Figure 2: Phases of insulin secretion. Top figure shows the two
characteristic phases of insulin secretion. First phase happens 5-10
minutes post-glucose stimulation, whereas the second phase is
sustained and takes about 1-2 hours. Bottom figure shows the
characteristic insulin secretion pattern observed in T2D line. First
phase is absent.
Mechanisms of insulin secretion
The primary mechanism of insulin secretion involves electrical activity in β-cells
in response to increased blood glucose level i.e., glycaemia. The best-characterized
pathway whereby glucose promotes electrical activity in insulin secreting β-cells involves
membrane glucose transporters (GLUT1 in humans or GLUT2 in rodents) that facilitate
glucose entry (Rorsman and Renstrom 2003). Once transported, glucose is
phosphorylated and metabolized via glycolysis increasing the ATP/ADP ratio. ATPsensitive K+ (KATP)-channels in normal conditions are open to maintain the membrane
6

potential around −70 mV (Drews, et al. 2010). Increase in the ATP/ADP ratio in β-cells
results in closure of KATP-channels and the consequent gradual decrease in K+
conductance, which depolarizes the β-cell. This depolarization gates voltage-dependent
L-type Ca2+ channels promoting Ca2+ influx and triggering exocytosis of stored insulin
granules (Drews et al. 2010).

The ATP-dependent K+-channels
Clearly, KATP-channels integrate and transduce glucose-generated metabolic
signals that culminates in membrane depolarization Ca2+ action potentials and insulin
secretion (Fig. 3). KATP-channels are the targets for sulfonylureas, which are commonly
prescribed oral agents for the treatment of T2D. The sulfonylureas, like glucose, close
KATP channels thus stimulating insulin secretion. The KATP-channels expressed in β-cells
are octameric complexes of two different units: the sulfonylurea receptor (SUR-1) and an
inward rectifier K+-channel (Kir6.2). SUR-1 not only binds sulfonylureas but also ATP
and therefore SUR-1 belongs to a superfamily of ATP-binding cassette proteins. ATP
also binds Kir6.2, the pore that conducts K+. Interestingly, sulfonylureas require the
presence of glucose to emulate the insulinotropic effects of glucose i.e., the plasma
concentrations of glucose that stimulate insulin secretion (Henquin 1998). Therefore,
additional mechanisms are present in β-cells allowing them to depolarize and secrete
insulin when K+-channels are closed [reviewed in (Henquin, et al. 2009)].

7

!

Figure 3: The ATP-dependent K+-channels. A) Under low
metabolic conditions, ATP-dependent K+-channels are open
keeping the β-cell hyperpolarized. B) When plasma glucose
increases, it is transported into the β-cell and metabolized
resulting in increased ATP/ADP ratios leading to the closure
of ATP-dependent K+-channels, membrane depolarization,
Ca2+ influx and insulin secretion from stored granules.
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In spite of the fact that KATP-channels transduce glucose signals into insulin
secretion, functional deletion of the genes encoding for subunits of these channels in mice
result in minimal changes in insulin secretion or remains unaffected regardless of glucose
levels, even under constant depolarization and bursts of Ca2+ action potentials (Best, et al.
2010). In humans, however, mutations in SUR-1 have been associated with congenital
hyperinsulinism; a rare disorder characterized persistent hyperinsulinemic hypoglycemia
(De Vroede, et al. 2004). Although SUR-1 mutations in mouse may not resemble the
human conditions, mice β-cells may potentially have redundant or additional mechanisms
involved in insulin secretion in response to glucose (Henquin et al. 2009).

The VRAC hypothesis
There is no doubt that KATP-channels play an important role in insulin secretion
(Henquin et al. 2009). Yet, in addition to the well-known KATP-channel-dependent
pathway, physiological concentrations of glucose can still promote β-cell's electrical
activity and insulin secretion even in the absence of functional KATP channel activity
(Best 2002; Best et al. 2010; Best, et al. 1992; Seghers, et al. 2000). The presence of
KATP-channel-independent pathways used by β-cells to secrete insulin was inferred from
the fact that low non-insulinotropic or normal concentrations of glucose i.e., 2.5 and 5
mM, respectively, inhibit KATP-channel-mediated 42K+ or 86Rb+ efflux from islets whereas
higher insulinotropic glucose concentrations i.e., >7.5 mM stimulate efflux (Lindstrom, et
al. 1988; Lindstrom, et al. 1986). Since the opening of K+-channels of any molecular
nature is predicted to hyperpolarize the membrane potential, it is clear that glucoseinduced insulin secretion happens due to activation of other ionic conductance, which is
9

not related to K+. Moreover, KATP-channel activity is inhibited or marginally present in
the presence of low concentrations of glucose (2.5-5 mM) and disappears at higher
glucose concentrations (Best et al. 2010). Thus, Len Best and co-workers have proposed
the concept that KATP-channels become activated at low glucose concentrations, for
instance, under starvation conditions, therefore hyperpolarizing the β-cell thereby
preventing insulin release. This explains why hypoglycemia does not happen under
normal fasting conditions and provides the basis for the proposition that additional K+independent ionic mechanisms involved in insulin secretion are present in β-cells (Best et
al. 2010).

!

Figure 4. The VRAC Hypothesis. Glucose enters β-cells via Glucose transporter 2
(GLUT2). Then, glucose is metabolized in Krebs cycle leading to increased ATP/ADP
ratio and intracellular osmolarity (right section). This increase in β-cell osmolarity
transiently increases cell volume which results in increased Cl– via volume activated Cl–
channels leading to plasma membrane depolarization independently of K(ATP)-channels.
Depolarization of the β-cell opens voltage-dependent Ca2+ channels promoting Ca2+ influx
and triggering insulin release from stored granules. A high [Cl–]i in β-cells ensures this
mechanism. NKCC1 is considered the main transporter involved in the maintenance of a
high [Cl–]i in β-cells.
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This additional KATP-channel-independent glucose-sensing mechanism in β-cells
involves glucose-induced electrogenic Cl− efflux through a volume-regulated anion
channel (VRAC), a concept originally hinted by Sehlin in 1978 after the observation that
a rise in glucose concentration stimulated

36

Cl– efflux from pre-loaded mouse islets

(Sehlin 1978). This concept was subsequently corroborated in different β-cells from
several species and has set the stage for the VRAC hypothesis to explain K+-independent
insulin secretion (Best et al. 2010), as explained in Figure 4.
Although the mechanisms whereby glucose activates the VRAC remain largely
unknown, it is believed that cell swelling induced by glucose itself and its metabolites
such as lactate may play a role in VRAC activation (Best et al. 2010). Independently of
the mechanisms of VRAC activation, electrogenic Cl− efflux is possible because the
intracellular chloride concentration ([Cl–]i) of β-cells is maintained higher than it would
be expected if Cl– ions were distributed across the plasma membrane strictly according to
the Nernst's equation. Indeed, fluorometric methods have determined that [Cl–]i in β-cells
is 34 mM, which is higher than expected from a passive distribution (Eberhardson, et al.
2000). Therefore, an inward transport of Cl– against its electrochemical gradient must be
present in β-cells (Fig. 4). This Cl– transport mechanism was identified as the BTDsensitive Na+K+2Cl– co-transporter 1 (NKCC1) (Best 2005; Majid, et al. 2001). The
relevance of NKCC1 in glucose-induced insulin secretion is evidenced by the fact that
both bumetanide (BTD) and furosemide, two potent diuretics inhibitors of NKCC,
directly block glucose-induced insulin secretion (Best 2005; Sandstrom 1990). These
findings have provided support to the suggestion that loop-diuretics may have
diabetogenic consequences (Furman 1981). However, these results were not obtained by
11

other investigators (Giugliano, et al. 1980; Robinson, et al. 1981) and thus, it remains
controversial weather or not BTD impairs glucose homeostasis.

BTD and carbohydrate metabolism
The VRAC hypothesis explains why loop-diuretics such as BTD and furosemide
impair insulin secretion in vitro or in vivo (Sandstrom 1988, 1990). Indeed, as mentioned
above, Na+K+2Cl– co-transporters (NKCCs), the main carriers involved in the
maintenance of high [Cl–]i are the targets of BTD (Gamba 2005).
It is important to mention that most of BTD is concentrated and eliminated in its
intact form by the kidney, a situation that ensures high concentrations of the drug in the
tubular lumen (Cohen, et al. 1976) where the kidney-specific isoform of the NKCCs i.e.,
NKCC2 is expressed. Therefore, BTD is a potent diuretic used to treat edema associated
to heart failure and hypertension (Garg, et al. 2007). Low concentrations of BTD,
however, are being used to treat neonatal seizures in the immature brain expressing
relatively high levels of one of the two known isoforms of the NKCCs: NKCC1 (Kahle,
et al. 2009). Inhibition of NKCC1 in immature neurons reduces Cl– influx keeping
GABA-mediated actions more hyperpolarizing (Kahle et al. 2009). In the β-cell, these
non-diuretic low doses of BTD may not impact insulin secretion. However, the impact of
BTD on [Cl–]i in β-cells may depend on the relative expression levels of NKCCs relative
to other Cl– carriers as well as to the presence of polymorphic alleles of these
transporters. Indeed, it has been recently shown that NKCCs exists as several
polymorphic variants (Fox, et al. 2007; Hiller, et al. 2006; Vrabec, et al. 2008; Walsh, et
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al. 2011), raising the possibility that some of them may have the potential to be more or
less sensitive to BTD than others.
This concept may help explain the apparently contradictory results related to the
role of BTD on glucose homeostasis in normal individuals. Indeed, in some studies BTD
impairs glucose tolerance, in others it improves or does not have an affect. For instance,
Giugliano et al. showed that chronic BTD treatment had no effect on insulin levels, but it
did increase glucose tolerance in humans. Furthermore, these authors suggested that BTD
could be even used as treatment of diabetes (Giugliano et al. 1980). On the contrary,
Robinson et al. showed a negative impact of BTD on basal insulinemia with no effect in
glucose tolerance in human (Robinson et al. 1981). In other mammals, such as dogs, rats
and mice, similar controversial results were obtained with BTD. For instance, the study
of Hermansen et al. showed that BTD has no effect in insulin secretion in pancreatic βcells isolated from dogs (Hermansen, et al. 1985) whereas Sandström showed that BTD
does inhibit insulin secretion by a direct effect of β-cells (Sandstrom 1988, 1990).
Therefore, based on the current knowledge regarding the role of diuretics in insulin
secretion, the apparently disparate effects of BTD on insulin secretion and glucose
homeostasis might be related to differences in expression of its targets e.g., NKCC1
splicing or allelic variants as well as unknown BTD targets.

The Slc12A family of cation-coupled chloride-co-transporter
The [Cl–]i is regulated by Cl– carriers and channels present in the plasma
membrane (Alvarez-Leefmans and Delpire 2009). All members of the solute carrier 12
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group A (Slc12a) family of cation-coupled chloride-co-transporter are directly involved
in the regulation of [Cl–]i. This family of co-transporters includes Na+-K+-2Cl– (Slc12a12) Na+-Cl– (Slc12a3) and K+-Cl– (Slc12a4-7) co-transporters (NKCCs, NCC and KCCs,
respectively). Topologically, these co-transporters are considered to share similar
structures consisting in 12 membrane-spanning segments and two intracellular N- and Ctermini [reviewed in (Di Fulvio and Alvarez-Leefmans 2009)] (Fig. 5). Functionally,
NKCCs and NCCs are transport mechanisms that accumulate Cl– in cells using the
energy stored in the Na+, K+ and Cl– chemical gradients, whereas KCCs mediate Cl–
extrusion driven by the products of the K+ and Cl– gradients (Adragna, et al. 2004;
Gamba 2005). Pharmacologically, NKCCs and NCCs are distinguished based on their
inhibitory profiles to diuretics. Indeed, BTD is a potent inhibitor of NKCCs whereas
NCCs are relatively insensitive to this drug. Conversely, NCCs are specifically inhibited
by thiazides whilst NKCCs are not. With the exception of D4, which is a specific
inhibitor of KCC2 (Austin and Delpire 2011), no specific pharmacological inhibitors of
KCC1, KCC3 and KCC4 are available (Adragna et al. 2004).

!

Figure 5: Slc12A family of cation-coupled chloride-co-transporters. This figure shows
the different ways of ion transport through cell membrane via NKCC, NCC and KCC.
NKCC transports Na+, K+, and 2Cl– ions, whereas NCC does not transport K+. KCC
transport K+ and Cl– outside the cell, which is just opposite what NKCC and NCC do.
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Slc12a2 (NKCC1) and Slc12a1 (NKCC2)
Two NKCC isoforms (NKCC1 and NKCC2) encoded by two different genes
Slc12a2 and Slc12a1, respectively, have been identified (Di Fulvio and AlvarezLeefmans 2009). NKCC1 is a ubiquitously expressed co-transporter whereas NKCC2 is
not. NKCC1 is involved in the maintenance of [Cl–]i above electrochemical equilibrium
and, in virtue of its high capacity to transport water (Hamann, et al. 2010), NKCC1
directly regulates cell volume in all cells tested so far (Hoffmann, et al. 2009). Under
basal isotonic conditions, NKCC1 is considered marginally active but it becomes
activated in osmotically shrunken cells, resulting in a net gain of K+-Cl– and water
thereby restoring the original cell volume [regulatory volume increase (RVI)] (Gagnon
and Delpire 2010; Hoffmann et al. 2009) (Fig. 6). It is known that transient osmotic
changes in cell volume regulate ion channels and transporters, including NKCC1
(Hoffmann et al. 2009). However, cell volume changes also regulate kinases and
phosphatases. Further, cell volume changes impact the organization of intracellular
organelles (Lee and Linstedt 1999) intracellular trafficking of proteins (Reinehr and
Haussinger 2007), hormone secretion (Best et al. 2010), cell growth and proliferation
(Stutzin and Hoffmann 2006).
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Figure 6: Regulatory volumes increase
and decrease (RVI & RVD). This figure
shows that NKCC is involved in
regulatory volume increase followed by
cell shrinkage due to hypertonicity,
whereas KCC does the opposite job and
is involved in regulatory volume
decrease following cell swelling. Figure
adapted from (Kahle, et al. 2008).
A detailed analysis of the mammalian Slc12a family of genes has been published
(Di Fulvio and Alvarez-Leefmans 2009). Here, we will briefly analyze some of them.
The mouse Slc12a2 gene produces two variants: mNKCC1a (RefSeq: NM_009194) and
mNKCC1b lacking exon 21 (Strausberg, et al. 2002). The rat Slc12a2 gene may produce
two splice variants as well. However, only rNKCC1a variant has been cloned
(AF051561) (Moore-Hoon and Turner 1998). The human SLC12A2 gene produces at
least three variants: hNKCC1a (U30246, AY280459) (Liedtke and Cole 2000; Strausberg
et al. 2002), hNKCC1b (BC144221 and BC146839) and hNKCC1c (BC033003) (Fig.
7A). Two coding exons are involved in the generation of potential hNKCC1variants:
exon 21 and exon 26. Like in the mouse, absence of exon 21 in hNKCC1 mRNAs
predicts hNKCC1b. The 26th exon of the human SLC12A2 gene contains an internal
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splicing acceptor site that divides the exon in two coding parts: exon 26a and 26b.
Inclusion of the whole exon 26 (a+b) generates hNKCC1c. Unlike hNKCC1b, hNKCC1c
has been cloned; it is predicted to encode a protein of 1151 amino acids with the unique
C-terminal sequence FYEPC as a consequence of including the first 66 bp of the 26th
exon (exon 26a). In spite of the fact that the role of NKCC1 in cell volume regulation is
well established, the relative contribution of each NKCC1 splice variant to this task
remain unknown. Further, the expression pattern and tissue distribution of hNKCC1b and
hNKCC1c remains to be determined.
Contrary to NKCC1, the products of the Slc12a1 gene (NKCC2) are considered
kidney-specific, and as such, the function of NKCC2 has been established: it absorbs ~30
% of the NaCl filtered by the glomeruli (Ares, et al. 2011). NKCC2s are 1095 amino acid
proteins with a predicted core molecular mass of ~120 kDa. The main difference between
NKCC2 variants locates in the amino acid sequence responsible for coding the second
putative trans-membrane (TM2) domain and part of the intracellular loop connecting
TM2-TM3 (see below), a region critically involved in ion transport (Gagnon and Delpire
2010). The importance of NKCC2 in kidney physiology is exemplified by mutations of
this co-transporter, which result in neonatal Bartter's syndrome type I, a disorder
characterized by severe dehydration, polyuria, electrolyte imbalance, and decrease blood
pressure (Simon, et al. 1996). Interestingly, NKCC2 has been recently found expressed
outside the kidney (Akiyama, et al. 2010; Akiyama, et al. 2007; Gavrikov, et al. 2006;
Kakigi, et al. 2009; Nickell, et al. 2007; Nishimura, et al. 2009). The functional impact of
NKCC2 in extra-renal tissues remains unknown.
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Figure 7: NKCC1 and NKCC2 splicing variants. A) NKCC1a (with no
splicing in its exons) have been cloned from mice, rat and human
sources, NKCC1b lacks exon 21 (brown). NKCC1c includes exon 26
(a+b). B) NKCC2 has three different splice variants: NKCC2A, B and F
includes exon 5 (green), 4 (blue) or 6 (brown), respectively (see text).

As mentioned, the members of the Slc12a family of genes (Fig. 8) are expressed
as several splice variants. In the mouse, three splice variants of NKCC2 are known:
mNKCC2A (variant 1, U20973), mNKCC2B (variant 2, U20974) and mNKCC2F
(variant 3, U20975) (Igarashi, et al. 1995) (Fig. 7B). They differ by the inclusion of one
of three mutually exclusive exons: exon 4 (B), 5 (A) and 6 (F) i.e., the ones encoding for
the amino acid differences in TM2-TM3. Similar variants have been cloned from the
rabbit kidney (Payne and Forbush 1994). In the case of the rat, two variants have been
cloned from kidney: Slc12a1 variant 3 [rNKCC2F, U10096 (Gamba, et al. 1994)] and
Slc12a1 variant 1 [rNKCC2A, BC087017 (Strausberg et al. 2002)]. Although the human
Slc12a1 gene has the potential to produce several splice variants, only one has been
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cloned from kidney: hNKCC2F [U5813 (Simon et al. 1996)].

The study of NKCC2 function relied heavily on heterologous expression systems
such as the Xenopus oocyte (Zeuthen and Macaulay 2012). This is partially due to the
consensus notion that NKCC2 is absent in mammalian cell lines. Furthermore, NKCC2
has been proven to be difficult to express and/or functionally detect in cell lines
(Hannemann, et al. 2009). Therefore, assessing NKCC2 function in a mammalian cell
context has been hampered by the lack of a mammalian cell model expressing
endogenous NKCC2. Although success has been recently achieved in transfecting fulllength constructs of NKCC2 in some cells (Benziane, et al. 2007; Zaarour, et al. 2011;
Zaarour, et al. 2009), the functional assessment of over-expressed NKCC2 may not
always correlate with its functional properties when endogenously expressed.

Animal models to study impact of NKCC on glucose homeostasis
Several animals model lacking functional NKCC1 have been established (Delpire,
et al. 1999; Flagella, et al. 1999; Pace, et al. 2000). Different strategies have been
followed to knockout Slc12a2 gene expression and function in mice. Regardless of the
strategy followed to generate NKCC1 null-mice or knockout mice (NKCC1 KO), these
mice share common phenotypic features. For instance, they have head imbalance
movements, circling and spinning behavior and apparent hyperactivity associated with
complete deafness. These behaviors are characteristic of inner-ear dysfunction (Delpire et
al. 1999; Flagella et al. 1999; Pace et al. 2000).
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Figure 8: Gene mutation disease of Slc12A family of cation-coupled chloride-cotransporter. Mutation in NKCC1 lead to broad effects like deafness, infertility,
imbalance and other manifestations as explained above. NKCC2 mutations cause
Bartter’s syndrome.

In spite of the importance of NKCC in the maintenance of [Cl–]i and the known
role of [Cl–]i in insulin secretion in vivo and in vitro, glucose homeostasis in NKCC1 KO
mice was never addressed. The present project sprouted in our lab during the
performance of behavioral tests of nociception using NKCC1 KO mice (Alshahrani, et al.
2012). We observed that these mice were aggressive, shaky and wobbly, particularly after
few hours of food deprivation. These clear, albeit unexpected signs of hypoglycemia
prompted us to investigate the role of functional inactivation of NKCC1 on insulin
secretion and glucose homeostasis.
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2- HYPOTHESES AND SPECIFIC AIMS
Hypotheses
1. Mice lacking functional alleles of NKCC1 have impaired insulin secretion in
response to glucose.
2. Bumetanide, a diuretic and potent inhibitor of NKCC1 impairs insulin secretion in
vivo and in vitro.

Specific aims
1. To determine the role of NKCC1 in insulin secretion and glucose homeostasis in
vivo in mice lacking both functional alleles of the Slc12a2 gene (NKCC1 KO).
2. To determine the role of low, non-diuretic doses of bumetanide on insulin
secretion in vivo in Slc12a2 gene targeted mice and in vitro in pancreatic islets
and β-cell lines.
3. To determine the molecular identity and pattern of expression of bumetanidesensitive co-transporters in islets and β-cell lines.
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3- MATERIAL AND METHODS
3.1 Materials
3.1.1. Enzymes, kits and chemicals
Pfx polymerase, RNase-OUT, SuperScript-III reverse transcriptase, random
hexamers, Lipofectamine2000 transfection reagent were from Invitrogen (Carlsbad, CA);
dNTPs, alkaline phosphatase and exonuclease I were from Affimetrix/USB (Cleveland,
OH); custom primers were from Integrated DNA Technologies (Coralville, IA); the
RNeasy mini kit was from Qiagen (Valencia, CA). General chemicals were from Sigma
(Saint Louis, MO). Tissue culture media, serum and supplements were from Fisher.
Microscopy supplies were from Electron Microscopy Sciences (Hatfield, PA).
3.1.2. Antibodies
Monoclonal antibodies against the C-terminal region of human NKCC1 (T4c) were
from Developmental Studies Hybridoma Bank, University of Iowa. Rabbit anti human
NKCC1 and β-actin antibodies were from Cell Signaling Technology (Danvers, MA).
Anti-NKCC2 antibodies were a kind gift from Dr. Pablo Ortiz (Henry Ford Hospital,
Detroit MI). Conjugated secondary antibodies for immunofluorescence application or
Western blotting were from Jackson Immunoresearch (West Grove, PA).
3.1.3. Animals
The studies involving genetically engineered mice were approved by the
Institutional animal care and used committee of Wright State University, Boonshoft
School of Medicine. Breeder mice lacking a single functional allele of the Slc12a2 gene
were created by Dr. Gary Shull [Department of Molecular Genetics, Biochemistry and
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Microbiology, University of Cincinnati (Flagella et al. 1999)] and kindly provided by Dr
F. J. Alvarez-Leefmans (Department of Pharmacology and Toxicology, Wright State
University). Mice of the three genotypes, i.e., wild-type (WT), lacking one
(heterozygous, HE) or two (knock-out, KO) functional alleles of the Slc12a2 gene were
generated by crossing HE mice breeders with WT mice of the C57BL/6J genetic
background. All animals were provided with standard chow diet and water ad libitum
with a 12-h light/dark cycle. Functional tests of glucose homeostasis were performed
with the help of Dr. Khalid Elased (Department of Pharmacology and Toxicology,
Wright State University) using mice aged between 21 and 23 days and fasted for 16 hs.
Body and pancreas weights were recorded for each animal used. Water and food intake
was determined in preliminary experiments to ensure no differences among genotypes.
Mice were genotyped by PCR using genomic DNA extracted from the tip of the mouse's
tail or other tissues post-mortem.
3.1.4. Cell lines
The rat insulinoma β-cell line INS-1E was a kind gift from Dr. Pierre Maechler
(Université de Genève, Faculté de Médecine). These cells were isolated from parental
INS-1E based on both their insulin content and their responses to glucose (Merglen, et al.
2004). INS-1E cells were grown in RPMI medium and equilibrated with 5% CO2 and 95
% air at 37C°. The medium was supplemented with 10 % fetal albumin serum, 75 µg/ml
streptomycin and penicillin sulfate. Cells were replated in T-75 flasks (BD Falcon,
Franklin Lakes, NJ) and stocked after confluence. Functional experiments involving INS1E cells were performed in confluent cultures in 6- or 12-well plates. Gene expression
experiments were performed in confluent cultures growing in T75 flasks. RIN-m5F is
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other rat insulinoma cell lines were involved in gene expression experiments using the
same environment of INS-1E as well. The mouse insulinoma β-cell line MIN6 was
kindly provided by Dr. Jun-Ichi Miyazaky (Department of Nutrition and Physiological
Chemistry, Osaka University Medical School). MIN6 cells were grown in accordance to
the original protocol (Miyazaki, et al. 1990). Briefly, MIN6 cells were grown in
Dulbecco's modified Eagle's medium (DMEM, 25 mM glucose) equilibrated with 5%
CO2 and 95 % air at 37C°. The medium was supplemented with 10 % fetal albumin
serum, 75 µg/ml streptomycin and penicillin sulfate. Cells were propagated in T75 flasks
and stocked after confluence. Functional experiments were performed in confluent cells
growing in 6- 12 or 24-well plates (BD Falcon, Franklin Lakes, NJ).
3.2. Methods
3.2.1. Isolation Islets
Mice islets were obtained and cultured following the protocol of Li et al. (Li, et al.
2009). Briefly, mice were euthanized and their liver/intestines exposed through an
incision around the upper abdomen. After clamping the duodenum wall to block the bile
path, pancreas was slowly perfused and distended with 10% FBS-RPMI/antibiotics
through the common bile duct. Then, pancreas were removed and placed in conical tubes
containing 2 ml of ice-cold DMEM. After washing two times in ice-cold DMEM (750xg
5 min), pancreas were transferred to a sterile 10 cm glass Petri dish to be chopped with
scissors (or surgical blades) into small pieces of ~1 mm3. Then, chopped tissues were
transferred to new tubes and digested using freshly prepared HBSS (define HBSS)- 3
mg/ml collagenase XI (1U/µl Sigma, C2014) for 3-5 min at 37.5ºC and vigorous shaking.
A second round of gentle digestion was allowed for an additional 3-5 min until complete
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digestion of the tissues. Digestion was stopped by placing the digestion reaction on ice
and by adding cold 1 mM CaCl2-HBSS. Islets were purified/washed by centrifugation
(290g, 30s, 4ºC) and resuspension in cold 1mM CaCl2-HBSS. Pure islets were
immediately processed for protein/RNA purification or plated in 6-well plate containing
RPMI supplemented with 10 % FBS, 75 µg/m1 streptomycin/penicillin sulfate. Islets
were allowed to attach by incubated them at 37°C for 3 days in RPMI. Once attached,
islets were ready for insulin secretion experiments.
3.2.2. Measurement of blood glucose levels
Blood glucose was determined in fasted animals using a Glucometer (FreeStyleLite, Abbott) and a single drop of blood (~3-5 µl) gently obtained from the tip of the
mice's tails. Briefly, the tail's skin was disinfected with alcohol prior to incising the tip.
No more than 1 mm of the end of the tail's skin was cut using sharp surgery scissors. This
procedure was applied to the animal only once and immediately before intraperitoneal
application of glucose or insulin to obtain basal values of glycaemia and/or insulinemia.
In the latter case, three to four drops of blood (~20 µl) was collected onto heparinized
capillary tubes.
3.2.3. Glucose and Insulin Tolerance tests
Glucose homeostasis in mice was evaluated following NIH's recommendations
(McGuinness, et al. 2009). Basal and post-stimulated glycaemia were determined using a
glucometer as explained above. Glucose and insulin tolerance tests (GTT) and insulin
tolerance tests (ITT) were performed by ip administration of 2 g/kg D-glucose or 0.75
U/kg of human recombinant insulin (HumulinR Eli Lilly & Co. Indianapolis, IN),
respectively. Glycaemia during GTTs were serially determined by blood sampling from
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the tip of the tail. Glycemia during ITTs was determined after 0, 20, 30 and 60 minutes of
insulin injection.
3.2.4. Sample collection for insulin assay
Blood samples were collected onto heparinized capillaries as explained above,
transferred to 200 µl tubes and immediately centrifuged 4 minutes at 18000xg to collect
plasma. Plasma samples were stored at −80°C for later use in insulin assay. The
supernatant of MIN6 or INS-1E cells growing under normal or glucose/drug-stimulated
conditions was used to determine insulin secretion. Briefly, MIN6 and INS-1E cells were
plated in 12-well plates at a density of 5×105 cells/well in complete DMEM media
(Lonza, Cat# 11960-044) supplemented with sodium bicarbonate and 450 mg/dl glucose,
10 % FBS and 50 µM 2-mercaptoethanol. On day one, cells were washed twice with
sterile glucose-free Krebs-Ringer Bicarbonate/HEBS buffer [KRBH: 2.7 ml of NaCl 5 M
(Sigma S5150), 4.8 ml KCl 75 mM (Sigma P9327), 562 µl NaHCO3 0.89M (Sigma
S8761), 100 µl NaH2PO4 0.5M (Sigma 94046), 50 µl MgCl2 1M (USB 78641), 150 µl
CaCl2 1 M (Sigma 21114), 1 ml HEPES 1 M (Sigma H0887), 100 mg Bovine albumin
(Sigma A7906), and deionized H2O to 100 ml]. After washing, cells were incubated for
30 minutes with 1 ml each well fresh KRBH supplemented with several concentrations of
glucose to generate a standard curve (Fig. 9). To test drug effects on insulin secretion,
cells were incubated with KRBH plus several concentrations of the drug. Bumetanide
stock (10 mM prepared in 0.1% NaOH) was diluted to give a final concentration of 10
µM, a concentration known to inhibit NKCC1 and NKCC2 (Gamba 2005). Then, glucose
was added as explained above. After 30 minutes, supernatants were collected, aliquoted
and stored at −80°C for later determination of insulin concentration.
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3.2.5. Insulin Assay
Insulin concentration in cell culture media and plasma was determined using a 96well format ultrasensitive enzyme-linked immunoabsorbent assay (ELISA) from APLCO
(80-INSMSU-E01). The method is based on a dual-monoclonal antibody sandwich
format where mouse monoclonal antibodies specific for insulin are immobilized to the
96‐well microplate as the solid phase and a horseradish peroxidase (HRP)
enzyme‐labeled monoclonal antibody results in insulin molecules being sandwiched
between the solid phase and the conjugated antibody.
!

Figure 9: Standard curve for insulin determination.
Plotted are the results of ten standards curves obtained in
ten different experiments shown in the sigmoidal
relationship between the log10 optical density (absorbance
at 510 nm) and the concentration of insulin (0.025-6.9
ng/ml). This relationship was used to calculate insulin
concentration in ng/ml in all our samples from plasma,
islets, or cell lines.

Insulin standards, diabetic controls and samples were analyzed in parallel
following the instructions of the manufacturer. Briefly, samples were incubated on an
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orbital microplate shaker at 700-‐900 rpm for 2 hours. After the first incubation was
completed, wells were washed and dried. TMB Substrate was added and the microplate
was incubated a second time on an orbital microplate shaker at 700-‐900 rpm for 30
minutes. Once the second incubation period was complete, Stop Solution was added, and
the optical density (OD) was measured by spectrophotometer at 450 nm with a reference
wavelength of 620-‐650 nm. The intensity of the color generated was directly proportional
to the concentration of insulin in the sample.
3.2.6. Immunohistochemistry
Immunohistochemistry refers to the process of localizing proteins in cells of a tissue
section by using antibodies. Mice were scarified and then perfused transcardially with ice
cold PBS to flush out the blood and then with 4 % paraformaldehyde (PFA) for 10
minutes. Tissues were collected and fixed in 4 % PFA overnight at 4°C. Tissues were
then sent to AML laboratories (Baltimore, MD) for paraffin embedding and microtomy.
Paraffin sections were deparaffinized by washing in xylene for 5 min and subsequent
hydration with 100 %, 95 %, 70 %, 50 % and 30 % ethanol for 5min each. Sections were
then rinsed with distilled H2O and PBS. Rinsed sections were transferred to water bath
containing 10 mM sodium citrate and boiled for 30 minutes. Boiled sections were
blocked using 3 % normal goat/horse/monkey serum (diluted in PBS containing 0.1%
Triton-X) for 1 hour at 4°C. Primary antibodies NKCC1 (1:500, T4c), NKCC2 (1:500),
insulin (1:500), and pro-insulin (1:500) were diluted in 3 % normal serum and sections
were incubated in diluted primary antibodies overnight at 4°C. The sections were then
washed with 1x PBS three times and incubated with their respective Cy3 and FITC
secondary antibodies for 2 hours at 4°C. NKCC1 was incubated with donkey anti-mouse
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secondary antibodies conjugated with FITC. NKCC2 was incubated with goat anti-rabbit
secondary antibody conjugated with Cy3. Slides were air-dried and mounted using a
mounting medium containing DAPI (Vectashield, Vector, Burlingame, CA). Images were
taken using a fluorescence microscope.
3.2.7. Immunofluorescence
Cell lines were grown on cover slips (Fisher Scientific. #NC9130114) placed on 6well plates. Cells have cultured in normal media (until ~60-75 % confluence) to provide
good imaging capabilities. Cells were washed three times with 1X PBS and fixed with
methanol 10 minutes at −20°C. Cells were permeabilized with 4 % fresh
paraformaldehyde + 0.25 % Triton X100. Cells plate were washed with 1X PBS three
times and blocked against non-specific staining using 3% normal goat/horse/monkey
serum for 1 hour at 4°C. Cells were washed again with 1X PBS and incubated with
primary antibodies. Primary antibodies NKCC1 (1:500), and NKCC2 (1:500) were
diluted in 3 % normal serum and cover slips were incubated in diluted primary antibodies
overnight at 4°C. Next day, slips were washed 3 to 4 times with 1X PBS and blocked
with their respective Cy3 and FITC secondary antibodies for 2 hours at 4°C. NKCC1 was
incubated with donkey anti-mouse secondary antibody conjugated with FITC fluorescent
dye. NKCC2 was incubated with goat anti-rabbit secondary antibody conjugated with
Cy3 fluorescent dye. Slips were air-dried and placed on slides by flipping them over and
placed on glass slips for microscopy (24x50mm, 1.5). Vectashield mounting medium
containing DAPI (Vector, Burlingame, CA) was used to counterstain cell nuclei. Images
were taken using Olympus FV1000 fluorescence microscope.
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3.2.8. Morphometric analysis
Cell number was computed using NIH ImageJ v1.42G software. Pancreas slides of
NKCC1 WT and NKCC1 KO mice were cimmunostained using polyclonal antibodies
against insulin coupled to HRP-conjugated secondary antibodies (DermPrep, Tampa FL).
Immunostained sections were visualized in a microscope and high-resolution images
were using oil immersion objectives at 600x magnification. Digital pictures were
converted to 8 bits and processed in silico. Insulin-positive cells were counted using the
cell counter plugin of ImageJ and this number was related to the total number of cells in
the islet. The area of β-cells was calculated from measured diameters in pixels and then
converted to µm3 assuming β-cells as spheres (volume = 4/3πr3) following described
procedures (Majid et al. 2001). At least 20 islets per genotype were analyzed.
3.2.9. Western blot analysis
Western blot analysis was performed in protein extracts obtained from tissues or
cell lines and was based on standard methods (Kurien and Scofield 2009). Briefly,
confluent cells were washed with 1X PBS three times and collected using scraper (rubber
policeman). Cells were washed by centrifugation in at 10,000xg for 10 min in phosphate
buffered saline (PBS) and lysed using lysis buffer containing protease inhibitors
(Complete LysisTM, Roche Diagnostics, Mannheim, Germany) with the help of a syringe.
When tissues were used as a source of protein extracts, the following procedure was
followed: tissues were quickly removed after euthanasia and homogenized on ice in lysis
buffer containing protease inhibitors. Tissue homogenates were centrifuged at 10,000xg
for 10 min at 4°C to remove cellular debris. Total protein content was determined in
supernatant using the Bradford method and BSA as a standard (BioRad, Hercules, CA).
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Fifty microliters (µl) of tissue lysate was added to 50 µl samples loading buffer (8% SDS,
125 mmol/L Tris-HCl, pH-6.8, 20% glycerol, 0.02% bromophenol blue, 100 mmol/L
dithiothreitol) and boiled for 5 minutes. Protein (50-100 µg per lane) was loaded into the
wells of a 4-20% SDS-PAGE gel and separated by electrophoresis for 1 hour. Proteins on
gel were then transferred (Bio-Rad transfer apparatus, Hercules, CA) to a 0.2 µm PVDF
membrane (Millipore, MA). The membrane was blocked for an hour with 10 % non-fat
milk in 10 mM Tris buffered saline with Tween 20 (TBS-T) at room temperature (RT).
For analysis of NKCC1, and NKCC2 membranes were probed over night on shaker at
4°C with mouse anti-NKCC1 (1:250), and rabbit anti-NKCC2 (1:250). Primary
antibodies were diluted in 5% non-fat milk in TBS-T. The membrane was then washed
with TBS-T buffer 3 times for 5 minutes at RT. The membrane was then incubated with
diluted horseradish peroxidase conjugated to donkey anti-rabbit (dilution 1:2000 in TBST), or donkey anti-mouse (dilution 1:2000 in TBS-T) secondary antibodies at RT for
1hour. The membrane was washed 3 times for 3 minutes using TBS-T buffer. Blots were
detected using SuperSignal Chemiluminescent substrate and visualized by exposing the
membrane for a minute using a Fujifilm image analyzer (LAS 3000, image Quant,
Sunnyvale, CA). The relative amounts of proteins of interest were determined by
normalizing to β-actin.
3.2.10. Reverse transcription coupled to the polymerase chain reaction (RT-PCR)
Total RNA was obtained from freshly isolated mouse islets, tissues or β-cell lines
using the RNeasy Protect Mini kit, following the instructions of the manufacturers. Total
RNAs/cDNAs from tissues were purchased from BioChain (Hayward, CA) or Zyagen
(San Diego, CA). First-strand cDNA synthesis and PCR was performed as described in
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detail in our recent publication (Alshahrani and Di Fulvio 2012). Briefly, 2 µg of total
RNA, 200 ng of random hexamers, 500 mM dNTPs, 10 mM DTT, 40 units RNase OUT
and 200 units of SuperScript III reverse transcriptase. Reverse transcriptions (RT)
reactions were incubated at 50ºC for 50 min. After RT, reverse transcriptase was
inactivated at 85ºC for 5 min. Aliquots of cDNA reaction were amplified using PCR in a
final volume of 50 µl and the following conditions: 0.5 mM of each dNTP, 1-2 mM
MgSO4 and 50 pmol of gene-specific primers. The thermal conditions for PCR (iCycler,
BioRad Hercules CA) were as follows: denaturation at 98ºC for 2 min, followed by 40
cycles of 30 sec at 95ºC; annealing, 30 sec at 58ºC and extension, 0.5-1 min at 68ºC,
according to primers and/or predicted amplicon length in bps. The sets of primers used to
amplify NKCC1, NKCC2 and control transcripts are detailed in Table 1. These primers
were also used to determine the nucleotide sequence of each RT-PCR fragment produced.
The nucleotide sequence of RT-PCR fragments was obtained in at least three amplicons
from separate RT-PCRs using different RNA samples. Sequences of overlapping RTPCR fragments were aligned and assembled in silico using and rat/mouse sequences of
reference (RefSeq) as template models.

32

!

Table 1. Primer-set sequences and identification. The sense and antisense sequences
of PCR primers used in this study are shown. PCR primers were designed according to
mouse, rat or human cDNAs and/or RefSeq nucleotide sequences. PCR primers were
designed to amplify transcript isoforms (i.e., NKCC1 and NKCC2) and to co-amplify
splice variants (i.e., NKCC1a, NKCC1b, NKCC2A, NKCCC2B and NKCC2F).
Primer sets composed by sense (forward) and antisense (reverse) primers are named
indicating the amplified transcript i.e., NKCC1, NKCC2, GAPDH, followed by
numbers reflecting the predicted length of the RT-PCR amplicon in base pairs (bp).
Primer sets were designed using Geneious Pro v5.5 (Biomatters Ltd. Auckland, New
Zaeland). Some of these primers were designed for other projects in collaboration with
Dr. Alvarez-Leefmans.

3.2.11. Quantitative real-time PCR
NKCC1 and NKCC2A transcript abundances relative to β-actin mRNAs in β-cells
were determined using iQ SYBR Green Supermix (BioRad, Hercules CA) following the
methodological details recently published (Alshahrani and Di Fulvio 2012) and the
guidance of Dr. David Cool and Billy Grunwald (Department of Pharmacology and
Toxicology, Wright State University). Briefly, total RNA from INS-1E β-cells growing
under basal conditions was used as template. NKCC1, NKCC2A and β-actin mRNAs
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were amplified using the following primer sets: NKCC2-150 sense: 5'-TGC TAA TGG
AGA TGG GAT GC-3', NKCC2-150 antisense: 5'-CAG GAG AGG CGA ATG AAG
AG-3'; NKCC1-149 sense: 5'-CAC GAT GAG CTG GAA AAG GA-3', NKCC1-149
antisense: 5'-ATG CAG CGG ACT AAT ACA CC-3'; and β-actin-220 sense: 5'-ACG
AGG CCC AGA GCA AGA GA-3', β-actin-220 antisense: 5'-GTG TTG AAG GTC
TCA AAC ATG ATC TGG GT-3'; and the following thermal conditions: initial
denaturation (hot-start) at 94 ºC 8 min plus 40 cycles at 94 ºC, 65 ºC and 72 ºC 30 sec
each. Control reactions in the absence of template were included for each primer set.
Samples were amplified in triplicates. Transcript quantification was based on the ΔCt
method where Ct is the cycle number at which the amount of amplified target mRNA
reaches the arbitrary threshold of 0.2 Relative Fluorescent Units above background.
NKCC1 and NKCC2 mRNA levels relative to β-actin were estimated using the relation:
target/actin = 2-ΔCt, where ΔCt is the difference between the mean Ct values for the target
transcript (NKCC1 or NKCC2) and β-actin i.e., ΔCt = CtActin - CtNKCCs.
3.2.12. DNA sequencing of PCR products
All RT-PCR products were sequenced to confirm molecular identity. For sequence
analysis of PCR products, 10 µl PCR reaction products were purified from single
stranded DNA and dephosphorylated using a mixture of exonuclease/alkaline
phosphatase enzymes [ExoSapit (Affimetrix/USB, Cleveland OH)] and incubated in
programmable thermocycler for 30 minutes at 37C° and 80C° respectively. Purified PCR
amplicones were sequenced using the same sense and antisense primes used to generate
the amplicons [Agencourt/Beckman Genomic Services (Beverly, MA)].
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3.2.13. In silico analysis
DNA sequences, chromatograms, alignments, primer design and annotation of new
transcript sequences were performed using Geneious software suite v5.5 (Biomatters Ltd.
NZ www.geneious.com) and several open source algorithms included in the software
suite such as MAFFT (Katoh, et al. 2002), Clustal W (Thompson, et al. 1994) or Primer3
(Rozen and Skaletsky 2000). Prediction of trans-membrane domains were performed and
interpreted using TOPCONS (topcons.cbr.su.se/index.php) as it has been recently
performed for members of the Slc12a family of genes (Di Fulvio and Alvarez-Leefmans
2009).
3.2.14. Statistical analysis
Data are expressed as means ± SEM. The trapezoidal method was used to determine
the area under the curve (AUC) of GTTs and ITTs. The difference between the means of
two populations was determined using Student’s two-tailed t-test after a preliminary Ftest to determine homogeneity of within-group variances. When more than two groups
were compared, the differences and significances in glycaemia or insulinemia were
determined using one-way ANOVA (GraphPad v5, Prism Software, San Diego CA). A
p<0.05 was used as the criterion for statistical significance. The homeostatic model
assessment (HOMA), an index of whole body insulin resistance, was calculated from
fasting plasma insulin concentration in µU/ml (ng/ml × 28.6 = µU/ml) and glycemia in
mM (mg/dl × 1/18 = mM) using the relationship HOMA = [Insulin] × [Glucose]/22.5.
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4- RESULTS
4.1. The Slc12a2 gene impacts insulin release and glucose homeostasis in vivo
The results of the next sections i.e., 4.1-4.8 have been submitted for publication
either in part of in whole. Direct evidence support the notion that the products of the
Slc12a2 gene i.e., NKCC1 and [Cl–]i are involved in insulin secretion in vivo and in vitro
[(Best et al. 2010) and references therein]. However, there is no direct evidence of a role
of NKCC1 insulin secretion. To determine the impact of the Slc12a2 gene in insulin
secretion in vivo we used mice harboring homozygous (NKCC1 KO) inactivation of this
gene. Basal plasma levels of insulin and glycaemia were determined in wild type
(NKCC1 WT) and NKCC1 KO mice in the morning after an overnight period of food
deprivation (~16 hs). As shown in Figure 10, the lowest plasma insulin concentration is
found in NKCC1 KO mice. As expected, fasting insulinemia in these mice correlated
with fasting glycaemia (Fig. 10). However, the HOMA index, a parameter that estimates
basal β-cell function and insulin sensitivity, calculated for NKCC1 KO was
approximately ten times lower than that of NKCC1 WT mice (HOMAKO=0.4 and
HOMAWT=4.3), suggesting that NKCC1 KO is more sensitive to insulin than NKCC1
WT mice.
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Figure 10: Basal glucose and insulin measurement. A) Glucose measurements test
(glycaemia test) of NKCC1 WT mice (n=9) and KO mice (n=9) after around 16 hours
fasting. One-way ANOVA followed by Newman-Keuls Multiple Comparison Test showed
there was a significant decrease in glucose of KO (62.2 ± 3.0 mg/dl) compared to WT
(101.2 ± 3.2 mg/dl). B) Basal insulin levels after 16 hours of food deprivation in NKCC1
WT and KO mice, n=5 for each group. One-way ANOVA followed by Newman-Keuls
Multiple Comparison Test showed there was a significant decrease in KO plasma insulin
(0.10 ± 0.01 ng/ml) vs. plasma insulin in WT (0.68 ± 0.25 ng/ml). *, p<0.0001. Data are
represented as mean ± SEM.

To test if NKCC1 KO mice are hypersensitive to insulin, hypoglycemia was
induced in fasting NKCC1 KO and NKCC1 WT mice by single intraperitoneal injection
of a standardized dose of human insulin (0.75 U/kg). Glycaemia was monitored during an
hour post insulin injection. As shown in Figure 11, insulin tolerance tests were not
significantly different in NKCC1 mice of each genotype, indicating that these mice,
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either NKCC1 WT or NKCC1 KO are equally sensitive to exogenously administered
insulin.

!

Figure 11: Insulin-induced hypoglycemia in NKCC1 WT and NKCC1 KO mice. A)
Shown are blood glucose concentrations obtained at the indicated times post-injection
of insulin. Every time-point represents glycaemia in mg/dl expressed as the mean ±
SEM. Time 0 represents time when glucose (2g/kg) was injected intraperitoneally.
Insulin tolerance tests were performed in fasting NKCC1 WT mice (black circles,
n=6) and NKCC1 KO mice (red circles, n=6). No statistical differences in glycaemia
at each time-point were found. B) Maximum hypoglycemic effect of insulin.
Glycaemia expressed as percentage drop form basal values (mean ± SEM, n=6 in each
group) 30 minutes post insulin load. No significant difference in insulin-induced
hypoglycaemia was recorded in these mice.

4.2. NKCC1 KO mice exhibit improved insulin secretion
Since hypoglycemia 30 minutes post insulin secretion reflects the first phase of
insulin secretion from β-cells (Gerich 2002a, b) and NKCC1 KO mice are
hypoinsulinemic relative to NKCC1 WT, our data suggest that NKCC1 KO mice have an
improved first phase of insulin secretion when compared to NKCC1 WT. To test this
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hypothesis, mice of both genotypes were treated intraperitoneally with a single dose of
glucose and plasma insulin concentration was determined 10 minutes post-injection. As
shown in Figure 12, plasma insulin levels increased after a load of glucose in these mice
irrespective of genotype. However, NKCC1 KO mice showed a higher insulin response to
glucose when compared to NKCC1 WT mice. Therefore, these results suggest that
NKCC1 KO mice are hypersensitive to glucose by a mechanism related to β-cells and
thus, challenge the notion that NKCC1 is required for insulin secretion.
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Figure
12:
Plasma
insulin
concentrations in NKCC1 WT and
NKCC1 KO mice. Plasma samples were
obtained from fasting mice at 0 and 10
minutes post-intraperitoneal injection of
glucose. Shown are plasma insulin
levels in NKCC1 WT (n=6) before (grey
bar) and 10 min after glucose load
(black bar) and in NKCC1 KO mice (n=
6, light red and red bars, respectively).
One-way ANOVA showed that there is
a significant increase in the response to
glucose in NKCC1 KO mice compared
to NKCC1 WT (*, p<0.001).

4.3. Islets lacking NKCC1 do not have impaired insulin secretion
To test the hypothesis that β-cells lacking NKCC1 are hypersensitive to glucose
and therefore improved insulin secretion in vivo, the secretory response of islets lacking
NKCC1 was tested in vitro. Islets of the two genotypes i.e., NKCC1 WT and NKCC1 KO
were incubated under low (2.5 mM) medium (5.5 mM) or high glucose concentrations
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(20 mM) for 1 hr. As shown in Figure 13, insulin secretion in NKCC1 KO islets shows
significant increase in glucose-induced insulin secretion comparing with NKCC1 WT
islets. As predicted by our hypothesis, islets lacking NKCC1 respond to lower
concentrations of glucose, whereas NKCC1 WT islets do not. Therefore, our results
demonstrate that Slc12a2 is not necessary for insulin secretion in response to glucose and
that absence of NKCC1 sensitizes β-cells to glucose.

Figure 13: Insulin secretion in primary
cultures of pancreatic islets. Islets obtained
from NKCC1 WT and NKCC1 KO mice were
isolated, cultured and exposed to 2.5, 5.5, and
20 mM glucose for 2 hours. Data represent
insulin concentration in the culture media
(mean ± SEM, n=10 for each group) expressed
as ng/ml (*, p<0.05 one-way ANOVA
followed
by
Newman-Keuls
Multiple
Comparison Test).
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4.4. NKCC1 KO mice exhibit improved glucose tolerance
Since the first phase of insulin secretion determines glucose tolerance and
clearance (Bruttomesso, et al. 1999), NKCC1 WT and NKCC1 KO mice were subjected
to intraperitoneal glucose tolerance tests (GTT). To this end, fasting mice were injected
intraperitoneally with a single dose of glucose (2 g/kg) and glycaemia determined at
several intervals during two hours. As shown in Figure 14, mean glucose levels during
GTT are lower in NKCC1 KO at critical time-points post glucose injection when
compared to those of NKCC1 WT mice. These results suggest that NKCC1 KO mice
have an increased ability to clear the injected glucose by a mechanism related to insulin
secretion. This is illustrated in the calculated area under each GTT curve (AUC,
mg/min/dl), a parameter reflecting insulin mobilization and/or sensitivity, and inversely
proportional to the glucose clearance. As shown in Figure 15, AUC of NKCC1 KO is
significantly lower than that of NKCC1 WT, suggesting that, contrary to expectations,
mice lacking both alleles of the Slc12a2 gene have improved glucose tolerance due to
increased glucose-induced insulin secretion.
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Figure 14: Intraperitoneal glucose tolerance tests (GTTs)
Shown are blood glucose concentrations obtained at the
indicated times post- injection of glucose. Every time-point
represents glycaemia in mg/dl expressed as the mean ± SEM.
Time 0 represents time when glucose (2 g/kg) was administered
intra-peritoneally. GTTs were performed in fasting NKCC1 WT
mice (black circles, n=17) and NKCC1 KO mice (red circles,
n=20) and the statistical differences in glucose concentrations at
each time-point were calculated using one-way ANOVA
followed by Newman-Keuls for comparison of multiple
determinations. Glycaemia was significantly lower in NKCC1
KO mice relative to NKCC1 WT at all time points (p<0.05).
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Figure 15: Area under the
curve of GTTs. The areas
under each glucose tolerance
test performed in NKCC1 KO
and NKCC1 WT mice were
calculated
using
the
trapezoidal rule. Results are
means ± SEM expressed in
mg/dl of glucose cleared in
120 minutes for NKCC1 WT
(n=17) and NKCC1 KO mice
(n= 20). *, p<0.05, one-way
ANOVA.

4.5. Homozygous inactivation of the Slc12a2 gene increases β -cell mass
The observed changes in glucose homeostasis in NKCC1 KO mice could be
explained by increased pancreatic β-cell mass. To ascertain this, we analyzed the β-cell
number within the islets and the number of islets within the pancreas morphometrically in
sections obtained from NKCC1 WT and NKCC1 KO littermates of 21 days of age and
immunostained against insulin. As shown in Figures 16 A-B, the number of β-cells/islet
appears to be higher in NKCC1 KO when compared to NKCC1 WT. To evaluate the
significance of this observation, insulin-positive cells per islet were counted using the
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NIH's software package ImageJ. As shown in Figure 16 C the number of β-cells was
increased in NKCC1 KO islets when compared to NKCC1 WT ones. The distribution of
β-cells (Figure 16 A-B) in NKCC1 KO or NKCC1 WT islets did not change; they were
the most abundant cells clustered in the core of the islets. Figures 16 D-E show the
number of islets in pancreas of NKCC1 KO compared to NKCC1 WT mice. Although the
difference in islet density between NKCC1 WT or NKCC1 KO mice was not significant
(Figure 16 F), the mean wet weight of NKCC1 KO pancreas was ~50 % lighter when
compared to NKCC1 WT mice. Similarly, total body weight of NKCC1 WT and NKCC1
KO mice aging 21-22 days was 11.1 ± 0.4 g (n=44) and 5.4 ± 0.2 g (n=23), respectively.
Therefore, these results support the hypothesis that NKCC1 KO have higher insulin
secretory reserve/capacity than NKCC1 WT mice due to an increased number of β-cells
per islet, a finding consistent with the high insulin response to glucose and the
consequent high glucose clearance observed in NKCC1 KO mice.
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Figure 16: β -cell mass in NKCC1 KO mice. A-B)
Representative insulin immunohistochemistry of
pancreas obtained from NKCC1 WT and NKCC1
KO mice. Pictures obtained at high magnification
to show differences in number and diameter of βcells. C) Quantification of the observed β-cell
number. Results expressed as β-cell number per
islet (mean ± SEM, *p<0.05). D-E) Same as A-B
but at low magnification to show differences in
islet number. F) Quantification of the number of
islets per µm2 of pancreas tissue. Results expressed
as mean ± SEM.
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4.6. Homozygous inactivation of the Slc12a2 gene decreases β -cell volume
Since NKCC1 transports water and regulates cell volume (Hamann et al. 2010;
Hoffmann et al. 2009; Zeuthen and Macaulay 2012) absence of NKCC1 in β-cells
predicts decreased cell volume. In turn, cell volume changes are known to regulate
insulin secretion in vitro (Miley, et al. 1998; Miley, et al. 1997). To determine if the
increased number of β-cells correlated with decreased cell volume, β-cell diameters were
determined using ImageJ and used to compute β-cell volume assuming them as spheres
(Majid et al. 2001). As shown in Figure 17, the mean cellular volume calculated for βcells lacking NKCC1 was statistically lower that that of WT. Although β-cell shrinkage
does not explain increased insulin secretion, increased [Cl–]i does. Therefore, our results
suggest that in the absence of NKCC1, additional mechanisms involved in [Cl–]i are
present in β-cells to ensure insulin secretion in response to glucose.
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Figure 17: β -cells volume determination. AB) Insulin immunohistochemistry performed in
pancreas tissues obtained from NKCC1 WT
and NKCC1 KO mice. C) Soma area of
insulin-immunostained β-cells in islets was
calculated from measured diameters in µm.
Shown are β-cell equatorial diameters
expressed as mean ± SEM, n>75 *p<0.05. Cell
volume can be calculated assuming β-cells as
spheres using the formula vol=3/4πr3, where r
is half of the cell diameter.
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4.7. BTD worsens glucose tolerance in NKCC1 KO mice
It has been suggested that BTD impairs glucose homeostasis through a direct
effect on insulin secretion (Furman 1981). However, these were controversial results
(Giugliano et al. 1980; Hermansen et al. 1985; Robinson et al. 1981). The facts that βcells express NKCC1, a protein known to transport Cl– against its electrochemical
gradient, that insulin secretion in response to glucose is blocked when [Cl–]i in β-cells is
set at electrochemical equilibrium (Eberhardson et al. 2000; Sehlin 1978) and that β-cells
lacking NKCC1 are shrunken and hypersensitive to glucose (previous results in this
Thesis) suggest that β-cells may not require Cl–-dependent pathways to secrete insulin or
that additional mechanisms are involved in the maintenance of high [Cl–]i in β-cells. To
examine the latter, we test the role of BTD on glucose homeostasis in NKCC1 WT and
NKCC1 KO mice. Baseline glycaemia was determined in fasting NKCC1 WT, and
NKCC1 KO mice 5 mins after a single intraperitoneal low dose of BTD (50 mg/kg).
Figure 18 shows that an acute dose of BTD significantly increases basal glycaemia in
NKCC1 WT mice, but it did not have a significant effect in NKCC1 KO mice's fasting
glycaemia suggesting that β-cells lacking NKCC1 are not acutely sensitive to BTD and
that basal glycaemia in these mice is kept normal by mechanisms that may not be related
to basal insulin secretion. However, these results do not exclude the possibility of a
potential impact of BTD on glucose-stimulated insulin secretion. To test this, we
examined the impact of BTD on glucose tolerance in NKCC1 WT and NKCC1 KO.
Fasting NKCC1 KO, and NKCC1 WT mice were subjected to GTTs 5 minutes after
intraperitoneal injection of BTD. As shown in figure 19, a single dose of BTD did impair
glucose tolerance in NKCC1 KO and NKCC1 WT mice. Indeed, AUCs of each curve
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after BTD irrespective of genotype were statistically higher when compared to those
obtained under normal conditions (Fig. 20). Taken together, these findings suggest that
BTD impairs insulin secretion in mice deficient in Slc12a2 gene and points toward the
existence of a BTD-sensitive mechanism involved in the maintenance of high [Cl–]i
which is different from NKCC1.

!

Figure 18: Effect of BTD on
basal glycaemia in NKCC1 WT
and NKCC1 KO mice. NKCC1
KO (red bars, n=7) and WT
(black bars, n=7) were treated
with a single low dose of BTD
(50 mg/kg) or vehicle (VEH,
NaOH 0.1 %) five minutes
before determination of blood
glucose
concentrations.
*,
p<0.05. Data are represented as
mean ± SEM.
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Figure 19: Glucose tolerance test post BTD treatment. Shown are blood glucose
concentrations obtained at the indicated times post- injection of glucose. Every
time-point represents glycaemia in mg/dl expressed as the mean ± SEM. Time −5
and 0 represents time when BTD (50 mg/kg) or glucose (2 g/kg) was administered
intra-peritoneally. GTTs were performed in fasting NKCC1 WT mice (black
circles, n=9) and NKCC1 KO mice (red circles, n=7) and the statistical differences
in glucose concentrations at each time-point was calculated using one-way
ANOVA followed by Newman-Keuls for comparison of multiple determinations.
Glycaemia was significantly lower in NKCC1 KO mice relative to NKCC1 WT
only in the first 30 minutes of the test (p<0.05).
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Figure 20: Area under the
curves. AUC of glucose
tolerance test (GTT) for
NKCC1 WT and KO at
baseline and after ip injection
of BTD 50mg/kg. Trapezoidal
method was used to calculate
AUC for each GTT curve.
One-way ANOVA showed a
significant increase in AUC of
KO with BTD compared to
KO before BTD dose. (n=8-9),
* p<0.05). Data are the mean ±
SEM of each group.

4.8. BTD inhibits insulin secretion in INS-1E β -cells and in islets of NKCC1 KO mice
To corroborate the previous results obtained in vivo the inhibitory role of BTD on
insulin secretion was tested in INS-1E β-cells. As expected, 10 µM BTD, a concentration
known to inhibit NKCC1 (Gamba 2005; Hoffmann et al. 2009), blocked glucose
stimulated insulin secretion without impacting basal insulin levels in INS-1E β-cell lines
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(Fig. 21). To confirm these results, the inhibitory role of BTD on insulin secretion was
tested in NKCC1 KO islets. As shown in Figure 22, BTD inhibits basal and glucose
stimulated insulin secretion from primary cultures of islets lacking NKCC1. This
unexpected result suggests the presence of a BTD-sensitive mechanism involved in basal
and glucose-stimulated insulin secretion and that this mechanism is not NKCC1.
Therefore, these results prompted us to search for potential BTD-sensitive Cl– transport
mechanisms in β-cells at the molecular level.
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Figure 21: Insulin secretion in INS-1E β -cells.
Determination of the insulin secretory capacity of
INS-1E β-cells in response to several concentrations
of glucose (5.5-20 mM). Cells were cultured until
confluence in 24-well plates and challenged with BTD
(10 µM, black bars) or vehicle (blue bars) and the
indicated concentrations of glucose for 2 h. Insulin
secreted to the culture media was determined and
expressed as % increase relative to 5.5 mM.
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Figure 22: Insulin secretion from islets lacking NKCC1.
A) Primary cultures of pancreatic islets obtained from
NKCC1 KO mice were challenged with two different
concentrations of glucose: 5.5 mM (100 mg/dl, black bar)
and 20 mM (360 mg/dl, blue bar). Results are represented
as insulin concentration in ng/ml of culture media (mean ±
SEM, *p<0.05). B) Impact of BTD on insulin secretion
from isolated islets obtained form NKCC1 KO mice. Islets
were incubated in the presence of BTD (10 µM) or vehicle
(NaOH 0.1%) for 2 h before challenging islets with
glucose (5.5-20 mM) for additional two hours. Results are
expressed as insulin concentration in ng/ml of culture
media (mean ± SEM, *p<0.05).

The next sections i.e., 4.9-4.13 reproduce, with permission of the publisher S.
Karger AG, Basel, our recent findings published in Cellular Physiology and Biochemistry
(Alshahrani and Di Fulvio 2012).
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4.9. β -cells express NKCC1a
NKCC1 is expressed in β-cells (Majid et al. 2001). However, it is unknown which
is the relative contribution of the two known NKCC1 splice variants i.e., NKCC1a and
NKCC1b to the total NKCC1 pool in β-cells. Therefore, the expression pattern of
NKCC1 variants was determined in primary cultures of mouse islets, rat and mouse βcell lines and different rat and mouse tissues. To this end, we first used the Basic Local
Alignment Search Tool (BLAST) to screen rat/mouse expressed sequence tags (ESTs)
posted in the NCBI's EST database (dbEST). As a query, we used mouse sequences
lacking exon 21 (NKCC1b, Fig. 23 A, top). The database search produced three matches
from rat tissues: BG666200, BG663902 and BG672434 (Fig. 23 A, center). Therefore,
rat tissues express NKCC1b and excluding the notion that this variant may not be
exclusive of the mouse and/or any particular tissue.
To confirm this concept, we used specific RT-PCR designed to co-detect
NKCC1a and NKCC1b mRNA expression in mouse islets, INS-1E β-cells and different
rat tissues such as kidney, pancreas, stomach, colon and dorsal root ganglia. The latter
tissue was used as positive control for the co-expression of NKCC1a and NKCC1b (Mao,
et al. 2012). To this end, we took advantage of the fact that rat and mouse ESTs
potentially encoding for NKCC1b mRNA lack 48 bp due to alternative exclusion of the
21st exon (Fig. 23 A) and this difference can be easily detected in PCR reactions designed
to co-amplify both transcripts. We used an NKCC1-specific set of PCR primers named
here NKCC1-525a/477b (Fig. 23 B, Table 1) designed to co-amplify in a single RT-PCR
reaction either rat or mouse NKCC1a and NKCC1b transcripts and to produce two
amplicons differing in length by 48 bp. As shown in Figure 23 C, RT-PCR products of
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predicted sizes for NKCC1a transcripts (525 bp) are detected in islets, β-cell lines and rat
tissues. As expected, transcripts corresponding to NKCC1a and NKCC1b were coamplified in dorsal root ganglia. Expression of NKCC1a as the sole Slc12a2 variant in
islets and β-cell lines was further confirmed by direct sequencing of the purified cDNA
fragment obtained with the NKCC1-525a/477b primer set in INS-1E β-cells (Fig. 23 D).
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Figure 23: A) Expression of NKCC1a and NKCC1b mRNA variants was screened in
dbEST using BLAST and a rat/mouse NKCC1b sequences encompassing exons 20/22
as a queries. Shown are the three EST clones that matched the queries: BG663902,
BG666200 and BG672434. To visualize the splicing event, these rat EST clones were
aligned against rat NKCC1a mRNA sequence of reference (NM_031798). B) Partial
representation of the mouse NKCC1 gene showing the predicted alternative spliced
exon 21 that encode for mNKCC1a (NM_009194) or mNKCC1b (predicted). Shown
are the last ten exons of the gene (filled boxes). Exon numbering is relative to the first
coding exon of the gene. The exon involved in alternative splicing (exon 21, 48 bp) is
indicated as a grey box. Introns are represented with V-shaped lines connecting exons.
White boxes represent the 3'-UTR of the mouse NKCC1 gene. The transcript region
predicted to be amplified with primer set NKCC1-525a/477b is also shown. C) RTPCR using total RNA from INS-1E, mouse islets (WT) and rat tissues. The NKCC1525a/477b primer-set, represented in B, was used to detect and discriminate
expression of NKCC1a and NKCC1b mRNAs in a single PCR reaction using rat or
mouse total RNA as template. A band of predicted size (525 bp) corresponding to
NKCC1a is detected in islets, INS-1E β-cells and in rat tissues tested, whereas two
bands corresponding to NKCC1a and NKCC1b (577 bp) were detected in total RNA
obtained from rat dorsal root ganglia (DRG). As negative control for RT-PCR
reactions, water instead of RNA was used. The primer set used in the control reaction
was GAPDH-555. D) DNA sequence chromatogram of the band of 525 bp obtained
by RT-PCR from INS-1E β-cells. Indicated is the region encompassing exons 20, 21
and 22. Reproduced with permission of the publisher S. Karger AG, Basel.
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4.10. β -cells express NKCC2A
Next, we determined the expression pattern of Slc12a1 gene products in β-cells.
Expression of NKCC2 transcript variants was analyzed by RT-PCR in transgenic islets
and in three β-cell lines: INS-1E, RIN-m5F and MIN6. Reverse transcribed total RNA
from these tissues/cells was PCR-amplified using several species-specific sets of PCR
primers designed to co-amplify splice variants of NKCC2 i.e., NKCC2A (Slc12a1 variant
1), NKCC2B (Slc12a1 variant 2) and NKCC2F (Slc12a1 variant 3) (Fig. 24 A, Table 1).
To amplify Slc12a1 transcripts we used four different primer sets: NKCC2-533, -1010, 700 and -878 (Fig. 24 A, Table 1). As shown in Figures 24 B-E, mouse islets and β-cell
lines express NKCC2 at the transcript level. To establish molecular identity of RT-PCR
amplicons, each PCR product obtained was sequenced in both directions. The partial
nucleotide sequence of the RT-PCR fragment obtained from INS-1E β-cells (700 bp) is
shown in Figure 24 F. In silico analysis of this sequence demonstrated ~99 % identity to
the corresponding region of rat NKCC2A sequence of reference (RefSeq NM_019134,
Fig. 24 G). Neither exon B nor F at the nucleotide sequence level was found in this
fragment. The nucleotide sequence of PCR fragments of 533 and 1010 bp also confirmed
the presence of exon A sequences (not shown).
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Figure 24: A) Representation of the rat NKCC2A (member 1) mRNA sequence of reference
(NM_019134). This mRNA is arranged in ~4.6 kb of nucleotide sequence transcribed from
the rat Slc12a1 gene. The gene contains 32 exons (filled grey arrows), 26 of which encode for
a protein (NKCC2A NP_062007) including the unique exon A (exon 5, white arrow). Exon
numbering is relative to the first coding exon. The predicted encoded protein of 1095 amino
acids is indicated as a black arrow atop the exons of the transcript. Underneath, the predicted
RT-PCR fragments to be obtained by using NKCC2 primer sets indicated in Table 1. These
fragments are represented as black arrows labeled NKCC2-533, NKCC2-1010, NKCC2-700
and NKCC2-878 to indicate that these primer sets are predicted to generate bands of 533,
1010, 700 and 878 bp, respectively. B-E) Expression of NKCC2 mRNAs in islets of WT mice
(B), RIN-m5F (C), INS-1E (D) and MIN6 (E) β-cell lines. Reverse transcription coupled to
PCR of islets or confluent cells' total RNA was performed using the primer sets indicated in
A. Shown are representative 2 % agarose gels where bands of predicted sizes for NKCC2 are
detected i.e., 533 bp (WT islets), 1010 bp (RIN-m5F), 700 bp (INS-1E) and 878 bp (MIN6).
As negative control, RT-PCR reactions were performed using H2O instead of total RNA and a
primer set designed to amplify transcripts for GAPDH. F) Partial nucleotide sequence of the
RT-PCR amplicon obtained with NKCC2-700 primer set. The 700 bp RT-PCR product
amplified from INS-1E cells was purified and sequenced in both directions by PCR using the
same primers (sense and antisense) used in the original amplification. Shown is a
representative chromatogram from 6 different amplification reactions. The sequence
chromatogram corresponds to the region encompassing exons A/B/F of the rNKCC2
transcripts. G) Alignment of chromatogram's nucleotide sequence against rat NKCC2A
sequence of reference. Showing is an exact match with exon A (exon 5) of NKCC2A
(NM_019134). Reproduced with permission of the publisher S. Karger AG, Basel.
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4.11. Molecular characterization of NKCC2 mRNAs expressed in β -cells
To provide convincing evidence of NKCC2A expression as the sole transcript of
the Slc12a1 gene expressed in β-cells, the complete open-reading frame (ORF)
containing 3'/5'-UTR sequences of NKCC2A mRNAs were PCR-amplified from INS-1E
and RIN-m5F cells in overlapping fragments and fully sequenced in both directions. The
full-length nucleotide sequences of NKCC2A expressed in INS-1E and RIN-m5F β-cell
lines have been submitted to GenBank under accession numbers JN579707 and
JN579708, respectively. Shown in Figure 25 is the nucleotide sequence and predicted
translation product of the Slc12a1 transcript expressed in INS-1E β-cells.
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Figure 25: Nucleotide and deduced amino acid sequences of NKCC2A expressed in
β -cells. Shown is the nucleotide sequence of NKCC2A mRNA (3934 bp, GenBank
JN579707) containing full 5' and 3'-UTRs (nt 1-215 and 3501-4595, respectively) and
an open reading frame (ORF) of 3285 bp (nt 216-3500) encoding a predicted 1095
amino acid protein represented with the single letter code.

In silico comparison of the predicted translated products of NKCC2A cDNAs
cloned from rat β-cell lines (JN579707 and JN579708) and rat kidney (BC087017)
(Strausberg et al. 2002) reveals ~100 % amino acid identity as in figure 26 A. However,
the full-length nucleotide sequence of rat β-cell NKCC2A cDNAs and NKCC2A cDNAs
cloned from rat kidney were different in many instances, including the third nucleotide of
several codons and, in particular, at their 5'-UTRs. As shown in Figure 26 A, alignment
of NKCC2A 5'-UTRs demonstrates that the rat Slc12a1 gene generates two differentially
spliced NKCC2A mRNAs. To provide experimental support to this finding and to rule
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out the possibility of β-cell line-related re-arrangements of the Slc12a1 gene, the genomic
region encompassing the predicted TSS and the first A1TG of the rat Slc12a1 gene (~1.6
kb) was PCR-amplified from INS-1E β-cells, sequenced and compared to the relevant
region of the rat Slc12a1 gene posted in NCBI's map viewer (NC_005102). As illustrated
in Figure 26 B, sequence analysis of the amplified genomic region demonstrates the
presence of two non-coding exons: named here exon -2 (22 bp) and exon -1 (64 bp),
located 10 and 75 bp downstream TSS, respectively. Exon -2 and exon -1 are separated
by a classic intron of 52 bp (intron -2), whereas an intron of 966 bp (intron -1) separates
exon -1 from exon 1, the one harboring the first in-frame A1TG codon. Together, our
results suggest that the Slc12a1 variant 1 (NKCC2A) expressed in β-cells is the result of
an alternative splicing involving exon -2 and exon 1.
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Figure 26: A) In silico alignment of the nucleotide sequence of rat NKCC2As corresponding
to the 5'-untranslated and coding regions. Shown are: the sequence or reference
(NM_019134), the kidney-derived clone (BC087017) and the two sequences obtained from βcells (JN579708 and JN579707). B) Representation of the rat NKCC2A 5'-UTR sequence of
reference aligned against the kidney-derived rat NKCC2A (BC087017). Shown is the noncoding exon of 64 bp (exon -1) located immediately up-stream exon 1, responsible for coding
the last 192 bps of 5'-UTR and the first in frame ATG codon. Also shown is the most distal
non-coding exon of the rat Slc12a1 gene (22 bp, exon -2) responsible for coding the first 22
nucleotides of the 5'-UTR. This exon is located 31 bp down-stream a putative transcriptional
initiation site (TTS, red arrowhead). The sense and antisense PCR primers used to amplify the
genomic region of the rat NKCC2 gene are indicated as opposite blue arrowheads. The
alternative splicing of the 5'-UTR region of NKCC2A expressed in INS-1E and RIN-m5F is
also indicated. Reproduced with permission of the publisher S. Karger AG, Basel.
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4.12. Expression pattern of NKCC2A transcripts
To determine the expression pattern of NKCC2A transcripts containing exon -2/-1
we performed RT-PCR experiments using exon -2/-1-specific primers and total RNA
from pancreas, β-cells and different rat tissues where NKCC2 mRNAs have been found
e.g., kidney and colon (Strausberg et al. 2002; Xue, et al. 2009; Zhu, et al. 2011). To this
end we used different sets of primers designed to co-amplify NKCC2A mRNAs
containing exon -1 (NKCC2-920A, -929A and -943A bp, i.e., ~900As bps) or exon -2
(NKCC2-686) (shown in Fig. 27 A, Table 1). As shown in Figure 26, exon -1 in
NKCC2A mRNAs is not found in INS-1E β-cells (Fig. 27B), colon (Fig. 27C) or
pancreas (Fig. 27D), but in kidney (Fig. 27 E), whereas NKCC2 mRNAs containing exon
-2 (686 bp) were found in these cells/tissues. To confirm molecular identity, the antisense
strand sequence of RT-PCR fragments from kidney and pancreas was obtained using
several nested reversed primers. Figure 27 F shows that NKCC2A expressed in pancreas
lacks exon -1. Hence, our results suggest that the Slc12a1 gene produces at least two
NKCC2A transcripts in the kidney, which are different in their 5' ends, but only one
outside the kidney, the one that lacks exon -1.
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Figure 27: A) Non-scale, partial representation of rat NKCC2A transcripts encoding exon −2
(white arrow, top) or exon −1 (black arrow, bottom) in their 5'-UTRs. Exons are represented
as grey arrows and are numbered according to the first coding one. Exon A (exon 5) is
indicated as a red arrow whereas the coding region of this partial representation is indicated as
a solid green bar on top of exons. Primer sets used for RT-PCR amplification of NKCC2A
transcripts differing in 5'-UTRs are indicated. Primer set rNKCC2-686 (exon −2)-specific is
designed to amplify rat NKCC2 transcripts expressing exon −2 as a single band of 686 bp.
Primer sets rNKCC2-900As (exon −1 and A)-specific comprise three pairs of primers:
rNKCC2-920A, -939A and -943A. These primer sets share identical sense primers but three
different ones specific for rat exon A (exon 5). B-E) Expression pattern of NKCC2A
transcripts in INS-1E (B), rat colon (C), rat pancreas (D) and rat kidney (E). Bands of
predicted sizes for NKCC2A transcript expressing exon −2 (686 bp) are detected in these
rodent tissues whereas mRNAs encoding for exon −1 were only found in kidney. Asterisks
denote the fragments sequences shown bellow. F) Partial nucleotide sequence of the RT-PCR
amplicons obtained with NKCC2-689 and NKCC2-943A primer sets. The 689 and 943 bp
RT-PCR products amplified from pancreas and kidney were purified and sequenced by PCR
using the antisense primers. Shown is a representative chromatogram from 3 different
amplification reactions. The sequence chromatogram corresponds to the region encompassing
exons exon −2, exon −1 and exon 1 of the rNKCC2A transcripts. Reproduced with permission
of the publisher S. Karger AG, Basel.
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4.13. NKCC2A, NKCC1a and insulin are co-expressed in β-cells
NKCC1 is expressed in β-cells but not in glucagon secreting α-cells (Majid et al.
2001) where [Cl–]i seems to be below equilibrium (Rorsman, et al. 1989). At the protein
level, NKCC1 expression was confirmed in INS-1E β-cells, pancreas and mouse islets by
immunoblotting using a monoclonal antibody directed against the C-terminus of human
NKCC1. As shown in Figure 28 A, NKCC1a is expressed in these cells and tissues as a
major band of ~170 kDa, consistent with its N-glycosylated molecular weight (Payne, et
al. 1995). As expected, NKCC1 expression was not found in islets purified from mice
deficient in Slc12a2 expression (KO, Fig. 28 A). Taken together, these results suggest
that only one splice variant of NKCC1 i.e., NKCC1a is expressed in β-cells.
To correlate the presence of full-length NKCC2A mRNAs in insulin-secreting βcells lines with expression of its predicted product, NKCC2A protein expression was
determined in β-cell lines and control tissues by immunoblot analysis of total
cellular/tissue protein extracts using a polyclonal antibody directed against the Cterminus of rat NKCC2. As shown in Figure 28 B, NKCC2A is detected in β-cells,
pancreas and islets as two bands, one of ~120 kDa (predicted core MW) and another of
~160 kDa (N-glycosylated), which is consistent with the known MWs of NKCC2 when
expressed in the kidney or in oocytes (Ares et al. 2011; Gamba 2005). Notably, NKCC2A
is detected in mice islets lacking NKCC1 (Fig. 28 B), hence providing evidence that the
polyclonal antibody used against NKCC2 does not cross-react with endogenous NKCC1.
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Figure 28: A) Immunoblot analysis of protein extracts
obtained from INS-1E β-cells, mouse pancreas or transgenic
islets of the three genotypes i.e., WT, heterozygous (HE)
and knock-out (KO) probed against NKCC1 using a
monoclonal antibody directed against the C-terminus of
human NKCC1. B) Immunoblot of INS-1E, pancreas and
normal transgenic mouse islets (WT) or lacking one or two
copies of NKCC1 (HE or KO, respectively). Detected are
bands corresponding to the core molecular weight of rat
NKCC2A (~120 kDa) and to its fully N-glycosylated
version (~170 kDa). Reproduced with permission of the
publisher S. Karger AG, Basel.
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To corroborate that NKCC2A is expressed in insulin-containing β-cells, we
performed immunofluorescence analysis of fixed pancreas using specific antibodies
directed against NKCC2 and pro-insulin as a marker of β-cells. Immunostaining of
pancreas sections obtained from mice lacking NKCC1 revealed the presence of
immunoreactive NKCC2A as a fine punctate distributed throughout the cytoplasm of
most but not all cells of the islet (Fig. 29 A, B). There was little if any staining in cells of
the exocrine secretory pancreas, where NKCC1 is abundantly expressed (Shumaker and
Soleimani 1999). To provide further evidence of NKCC2A protein expression in β-cells,
we performed double labeling immunofluorescence experiments in mice islets using a
monoclonal antibody against pro-insulin and NKCC2. As shown in Figures 29 C-E,
NKCC2A is detected in cells of the islet that express pro-insulin (β-cells). To extend and
further

confirm

co-localization

of

NKCC1a

and

NKCC2A

in

β-cells,

co-

immunofluorescence experiments were performed in the rat β-cell line INS-1E. As
expected, NKCC1a and NKCC2A are co-expressed in these β-cells (Fig. 30).
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Figure 29: A-B) Representative indirect immunofluorescence
of a pancreas slides obtained from NKCC1 WT and NKCC1
KO mice showing immunoreactivity in most but not all cells of
pancreatic islets. C-E) Co-immunolocalization of NKCC2A and
pro-insulin in rat pancreas. Pancreas slides were coimmunostained using a monoclonal antibody directed against
pro-insulin (GS-9A8) and anti-NKCC2 antibodies. FITC- and
Cy3-conjugates secondary antibodies were used to label proinsulin and NKCC2A, respectively, whereas nuclei were
counterstained using DAPI.
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Figure 30: A-B) Representative indirect immunofluorescence of
INS-1E β-cells growing in coverslips. T4 and anti NKCC2
antibodies coupled to FITC- and Cy3-conjugated secondary
antibodies were used to label NKCC1 and NKCC2A,
respectively, whereas nuclei were counterstained using DAPI.
Shown are NKCC1 (green) and NKCC2 (red) immunoreactivity
in most of the cell cytoplasm and towards the plasma membrane.
Results submitted for publication in conjunction with results in
sections 4.1-4-8 to the Journal of Endocrinology.
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5- DISCUSSION
The "volume regulated anion channel" (VRAC) hypothesis for glucose-induced
insulin secretion place [Cl–]i above electrochemical equilibrium in β-cells as a key player
in the first phase of glucose-induced insulin secretion (Best et al. 2010). This hypothesis
is based on several observations published in the last thirty years or so. Indeed, the first
recognition that [Cl–]i in β-cells plays a role in insulin secretion was published in 1978
(Sehlin 1978). Later on, Sehlin's findings were confirmed and extended to many different
settings (Best 2005; Eberhardson et al. 2000; Kinard and Satin 1995; Lindstrom et al.
1988; Lindstrom et al. 1986; Somers, et al. 1980; Tamagawa and Henquin 1983). Today,
ample evidence support the notion that [Cl–]i is maintained above electrochemical
equilibrium by BTD and furosemide-sensitive NKCC1 (Eberhardson et al. 2000; Majid et
al. 2001), the only NKCC isoform detected so far in β-cells. A high [Cl–]i makes possible
the long recognized electrogenic Cl– efflux from β-cells in response to glucose, thus
contributing to the well-known effect that insulinotropic glucose concentrations have on
β-cell membrane depolarization and insulin release (Best et al. 2010; Best and Yates
2010).
In spite of those facts, however, we found that mice lacking NKCC1 have
improved insulin secretion, rather than impaired. Indeed, NKCC1 KO mice had a robust
insulin response to glucose when compared to NKCC1 WT mice. Further, NKCC1 KO
mice have improved glucose tolerance than mice harboring intact Slc12a2 genes (Fig.
14). Since the first phase of insulin secretion determines a better glucose tolerance and
clearance, our results strongly suggest that the relatively flat glucose tolerance observed
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in NKCC1 KO mice after a standardized intraperitoneal dose of glucose is due to
hypersecretion of insulin. This is confirmed in our results of disproportionately increased
insulin secretion in NKCC1 KO mice 10 minutes post glucose administration (Fig. 12).
These results were further confirmed by calculating the areas under each GTT curve.
Indeed, AUCs were significantly decreased in NKCC1 KO compared to NKCC1 WT.
These findings suggest that NKCC1 KO mice have a better ability to clear glucose than
that of WT due to increased glucose-stimulated insulin secretion.
This surprising finding cannot be easily put in line with the VRAC hypothesis
considering that our experiments clearly indicate that NKCC1 is neither necessary nor
sufficient for insulin secretion. Many factors may influence insulin secretion in vivo,
particularly in NKCC1 KO mice known have significantly less body weight than NKCC1
WT littermates and present several conditions potentially related to reduced caloric intake
and salivation impairment in NKCC1 KO mice (Evans, et al. 2000; Flagella et al. 1999).
It can be argued that this difference is sufficient to promote glucose carving and increase
tissue sensitivity to insulin, thus offering an explanation on the low plasma levels of
insulin and low glycaemia observed in NKCC1 KO mice (Fig. 10). However, these
differences were clearly not feed-related. Indeed, autopsies of NKCC1 KO mice before/at
weaning time always revealed amounts of milk in their stomachs comparable to NKCC1
WT littermates. Moreover, after weaning, they feed normally (data not shown).
Interestingly, at weaning time, some NKCC1 KO mice showed behavioral abnormalities
such as tremor, food aggression and excitability, particularly after overnight fasting
period, consistent with symptoms of hypoglycemia.
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These in vivo findings may also explain low glycaemia and insulinemia in
NKCC1 KO mice relative to NKCC1 WT due to increased tissue sensitivity to insulin.
To determine this, the homeostatic model assessment (HOMA), a parameter to estimate
the whole body insulin resistance for these mice was calculated. HOMA in NKCC1 KO
was ten times lower than that of NKCC1 WT mice, suggesting that NKCC1 KO mice are
either hypersensitive to insulin or their β-cells are hypersensitive to glucose. Should the
first case hold true, it would be expected that NKCC1 KO mice would reach
hypoglycaemia faster than NKCC1 WT after a standardized intraperitoneal dose of
insulin. However, insulin induced hypoglycemia in these mice did not differ among
genotypes strongly suggesting that NKCC1 KO and NKCC1 WT mice are equally
sensitive to insulin (Fig. 11). Therefore, increased glucose tolerances in NKCC1 KO
mice do not appear to be related to increased insulin sensitivity of peripheral tissues to
insulin, but to increased sensitivity of β-cells to glucose. Our findings regarding low
basal insulinemia and glycaemia in mice lacking NKCC1 may be related to increased
sensitivity of β-cells to glucose. Indeed, the same standardized doses of glucose produced
disproportionate insulin responses in mice lacking NKCC1 relative to WT (Fig. 12).
These observations prompted us to investigate the impact of NKCC1 inactivation
on insulin secretion. NKCC1 KO mice had a robust insulin response to glucose when
compared to NKCC1 WT mice. It could be argued that the increased insulin secretion
observed in NKCC1 KO mice is due to the fact that NKCC1 KO mice are hyperkalemic
(Wall, et al. 2006) and to the known impact that chronic hyperkalemia has on insulin
secretion (Martinez, et al. 1991). However, islets from NKCC1 KO mice responded
better to glucose that those obtained from NKCC1 WT (Fig. 13), even at concentrations
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of glucose known to be non-insulinotropic thus suggesting that islets lacking NKCC1 are
more sensitive to glucose than those of NKCC1 WT mice.
Increased sensitivity of β-cells to glucose can be explained by increased β-cell
mass (Bouwens and Rooman 2005). Indeed, increased number of β-cells in pancreatic
islets would result in exaggerated insulin response to glucose when compared to a normal
β-cell mass. In line, we found that NKCC1 KO mice have increased β-cell mass (Fig.
16). Although this finding helps to explain increased insulin responses to glucose
observed in NKCC1 KO mice (Fig. 12), per se it does not explain increased insulin
secretion neither in vivo nor in vitro without considering [Cl–]i above electrochemical
equilibrium. Therefore, it appears that in addition to increased β-cell number an increased
[Cl–]i is necessary to support the notion that β-cells lacking NKCC1 are hypersensitive to
glucose. It has been demonstrated that membrane ion channels and transporters are
important for cell proliferation (Hoffmann 2011; Ohsawa, et al. 2010; Panet, et al. 2002;
Panet, et al. 2000; Stutzin and Hoffmann 2006). For instance, Cl– channels play a key
role in S phase progression of the cell cycle (Ohsawa et al. 2010). Further, NKCC1
promotes cell proliferation, mitogenic stimulation and transformation and its inhibition
with BTD or furosemide reduces cell proliferation (Panet et al. 2002; Panet et al. 2000).
Mechanistically, NKCC1 indirectly provokes activation of ERK/MAPK signal
transduction pathways controlling cell proliferation (Panet et al. 2002). The link between
NKCC1 and cell proliferation may be related to [Cl–]i above equilibrium or to the fact
that L-type Ca2+ channels abundantly expressed in β-cells are known to be indirectly
sensitive to a drop in [Cl–]i (Babai, et al. 2010; Henquin 1998; Jakab, et al. 2006). In turn,
[Ca2+]i is necessary for β-cells proliferation (Nguidjoe, et al. 2011). Therefore, either
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persistently high [Cl–]i or [Ca2+]i are predicted to impact β-cells proliferation. In line, it
has been recently reported that [Cl–]i above equilibrium is required for G1-to-S
progression of the cell cycle (Ohsawa et al. 2010) and chronically high [Ca2+]i increases
β-cells mass (Nguidjoe et al. 2011). Therefore, high [Cl–]i and [Ca2+]i in β-cells lacking
NKCC1 may explain our findings. However, a high [Cl–]i in β-cells lacking NKCC1
requires a transporter with the potential to upload Cl– against its electrochemical
equilibrium.
In the absence of NKCC1, other genes may potentially be involved in the
regulation of [Cl–]i in β-cells. These cells express some anion exchangers of the family
Slc4a, Slc26a and Slc9a known to exchange Cl– and HCO3– (AEs) or Na+ and H+ (NHEs)
(Best, et al. 1996; Miley et al. 1998; Miley et al. 1997). However, the most abundant
member of the Slc9a gene family expressed in islets i.e., NHE1 has little or no role on
glucose-induced insulin secretion (Stiernet, et al. 2007). On the contrary, the widely
expressed disulfonic stilbene (DIDS)-sensitive Cl−/HCO3− exchanger-2 (AE2) may be
involved in [Cl–]i regulation in β-cells. In fact a DIDS-sensitive Cl−/HCO3− exchanger of
unknown molecular identity was proposed to be involved in transient insulin secretion
under hypotonic conditions (Best et al. 1996). Additional potential candidates implicated
in [Cl–]i regulation in β-cells may be the products of the Slc12a1 and Slc12a3 genes.
Interestingly, hydrochlorothiazide, an inhibitor of the Slc12a3 gene product NCC,
inhibits insulin secretion from cultured islets. However, this effect was not related to the
known ability of NCCs to regulate [Cl–]i (Sandstrom 1993). It is worth mentioning that
we did not find convincing molecular evidence of NCC transcripts expressed in rat βcells lines (data not shown). Although our results do not exclude the possibility of very
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low levels of the transcript or its protein, it remains to be established if the observed
effect of hydrochlorothiazide on insulin secretion is due to mechanisms dependent or
independent of NCC in β-cells.
Based on the known facts that BTD inhibits insulin secretion in vitro and in vivo
(Sandstrom 1988, 1990), that [Cl–]i at equilibrium blunts β-cell response to glucose
(Lindstrom et al. 1988; Lindstrom et al. 1986; Sehlin 1978) and that BTD had
controversial effects on glucose tolerance in man and other mammals (Furman 1981;
Giugliano et al. 1980; Hermansen et al. 1985; Robinson et al. 1981) we reasoned that the
variability in BTD outcomes may be related to expression variability of genes involved in
Cl– handling. To test this possibility, we first studied the effect of BTD on glucose
tolerance in mice lacking NKCC1. To our surprise, we found that BTD does impair
glucose tolerance in NKCC1 KO mice as well as in NKCC1 WT without impacting basal
glycaemia in the former. Although the effect of BTD on NKCC1 KO mice glucose
tolerance may be a consequence of mechanisms not related to insulin secretion, we found
that BTD also blocked insulin secretion from islets lacking NKCC1 (Fig. 22) as well as in
β-cell lines (Fig. 21) therefore indicating that BTD may impair glucose tolerance in mice
lacking NKCC1 by a direct effect on β-cells.
This new hypothesis required the presence of a BTD-sensitive Cl– transport
mechanism in β-cells, which in turn must be functional in β-cells lacking NKCC1. At
least to non-exclusive possibilities explain our results: i) β-cells of NKCC1 KO mice
express a new NKCC1 variant where the targeted exon 6 of the gene is spliced out
generating a BTD-sensitive NKCC1 variant with the potential to regulate [Cl–]i and ii)
NKCC2 is expressed in β-cells. To test the first hypothesis, we screened gene expression
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of all potential transcripts produced by the Slc12a2 gene in β-cells lines, islets and
tissues, including those from NKCC1 KO mice. Using RT-PCR, NKCC1 mRNA
expression was confirmed in β-cells and islets and its molecular identity established as
NKCC1a (Fig. 23). We did not find evidence of NKCC1b expression in β-cells and other
tissues such as pancreas, kidney, colon or stomach (Fig. 23C). These were expected
findings based on the current notion that NKCC1a, not NKCC1b is the most abundantly
expressed variant in polarized epithelia (Carmosino, et al. 2008). Further, we found both
NKCC1a and NKCC1b transcripts in neurons of dorsal root ganglia, in agreement with
recent work (Mao et al. 2012). Therefore, the possibility that undetectable levels of
NKCC1b in β-cells are the result of inappropriate primer design is minimized.
To test the second hypothesis, the one stating that NKCC2 is expressed in β-cells,
we followed a similar approach as for NKCC1. This study clearly demonstrated that
NKCC2 is expressed in insulin-secreting β-cells (Fig. 24 B). Although this unexpected
finding argues against the long-standing paradigm that NKCC2 mRNAs and proteins are
exclusive of the tubular cells (Ares et al. 2011; Gamba 2005; Gamba et al. 1994), it has
become clear that NKCC2 is expressed outside the kidney. Molecular, immunological
and/or functional evidence of NKCC2 expression has been found in several kinds of
neurons or interneurons such as the ones of mesenteric ganglia, enteric secretomotor or
starburst amacrine (Gavrikov et al. 2006; Xue et al. 2009), and in cells of the gastric,
intestinal, endolymphatic sac and olfactory epithelia (Akiyama et al. 2010; Akiyama et al.
2007; Ji, et al. 2012; Kakigi et al. 2009; Nickell et al. 2007; Nishimura et al. 2009; Xue et
al. 2009; Zhu et al. 2011). In fact, it is apparent that NKCC2 is present widely among
tissues, although at lower levels when compared to kidney [reviewed in detail in (Di
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Fulvio and Alvarez-Leefmans 2009)]. In line, real time quantitative PCR experiments
demonstrated low levels of NKCC2 transcripts in β-cells; almost 10 times less abundant
than those for NKCC1a (Alshahrani and Di Fulvio 2012). These results raise the
possibility that NKCC2 may play a secondary/less prominent role in total cellular NKCC
transport. However, protein data does not support this notion. In spite of the fact that
NKCC2 transcripts were less abundant than NKCC1 mRNAs, at the protein level such
relationship was not conserved suggesting that NKCC2 mRNAs may be efficiently
translated into protein in β-cells.
The relatively abundant NKCC2 protein expressed in β-cells may be result of
mRNAs with specific features, particularly at their 5'- or 3'-untranslated regions (UTR).
To gain insights into the molecular identity of NKCC2 transcripts, we amplified and
sequence the full-length NKCC2 mRNA expressed in two different β-cell lines (Figure
25). The results clearly demonstrate that it is the Slc12a1 variant 1 (NKCC2A) the
NKCC2 spliced version expressed in β-cells and outside the kidney (Figs. 24)
(Alshahrani and Di Fulvio 2012). We did not find evidence of other members of the
NKCC2 family, namely NKCC2B or NKCC2F. In silico analysis of full-length rNKCC2
cDNAs cloned from two different β-cell lines demonstrated the presence of an open
reading frame (ORF) predicted to encode a protein of 1096 amino acids 100 % identical
to NKCC2A protein translated from a cDNA cloned from rat kidney (BC087017) and the
rat NKCC2A protein sequence of reference (NP_062007). However, the nucleotide
sequence corresponding to the 5'-UTR region of β-cell's NKCC2A was different from
BC087017 and from the rat NKCC2A mRNA sequence of reference posted in RefSeq
database (NM_019134). Indeed, an alternative splicing event was evident in NKCC2A 5'78

UTR. We found two short non-coding exons (i.e., exon −2 and exon −1) located
downstream from the putative TATA box and up-stream from the first coding exon of the
rat Slc12a1 gene. Hence, we provide for the first time evidence that NKCC2A mRNAs
expressed in β-cells or outside the kidney are the result of alternative splicing involving
exon −2 and the first coding exon 1 of the slc12a1 gene (Alshahrani and Di Fulvio 2012).
Although the differences in NKCC2A 5'-UTRs are due to a variation between an
NKCC2A mRNAs expressed in the kidney and non renal tissues, we did not find
evidence of exon −2 expression in the form of ESTs from many species (data not shown).
However, the nucleotide sequence of the first cloned full-length rat Slc12a1 (variant 3,
NKCC2F, U10096) does contain exon −2/exon 1 splicing, thus demonstrating that the rat
Slc12a1 gene can express exon −2 in the rat kidney, at least as part of variants 1 and 3.
Exon −1, however, was found in a single EST from rat kidney (CK483746) and in a fulllength NKCC2A cDNA (BC087017) (Strausberg et al. 2002).
These results demonstrate that two NKCC2A transcripts can be found in rat
tissues that are different in their 5' ends: one encoding exon −2 in the kidney and extrarenal tissues, and another encoding exon −1 in the rat kidney only (Alshahrani and Di
Fulvio 2012). The existence of two NKCC2A mRNAs encoding for one protein in rat
kidney tissues suggests that either different TTSs and/or core promoter elements are
functionally present in the rat Slc12a1 gene, as bioinformatic analysis of Slc12a1 genes,
which have been already predicted (Di Fulvio and Alvarez-Leefmans 2009). The
difference in 5'-UTRs may impact NKCC2A expression levels outside the kidney, either
in a developmental stage-specific and/or temporal manner, and/or the stability of the
mRNAs and/or efficiency of its translation. Additional experiments are needed to
79

determine if different 5'-UTR NKCC2A variants are the result of activation of different
promoters acting and/or regulated in a tissue-restricted manner.
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6- COUNCLUSION
β-cells keep [Cl–]i higher than equilibrium (Eberhardson et al. 2000), which in
turn plays an important role in plasma membrane depolarization and insulin secretion
(Best et al. 2010; Henquin et al. 2009). NKCC1 has been proposed as the co-transporter
involved in regulation of [Cl–]i in β-cells and thus considered an important player in
insulin secretion (Best 2005). Our study suggests that insulin secretion in response to
glucose is conserved if not improved in mice lacking NKCC1 and that BTD-sensitive
mechanisms different from NKCC1 are involved in insulin secretion (results submitted).
We have found that NKCC2A is expressed in β-cells and that this co-transporter,
NKCC1, and pro-insulin are co-expressed in the same cells (Alshahrani and Di Fulvio
2012). Therefore, our results provide evidence supporting the new concept that NKCC2
may contribute to the control of the ion environment within β-cells, particularly [Cl–]i and
therefore NKCC2 may be involved in insulin secretion. Although the exact mechanisms
whereby [Cl–]i regulates insulin secretion in response to glucose remain to be determined,
the electrogenic efflux of Cl– from β-cells enabled by the action of NKCCs contributes to
glucose-induced

membrane

depolarization
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therefore

insulin
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APPENDIX A
NKCC1 expression regulation by loop-diuretics
Saeed Alshahrani & Mauricio Di Fulvio.
Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright
State University, Dayton, OH
Na+K+2Cl– co-transporters are secondary active transport proteins involved in cell
volume regulation and in the maintenance of the intracellular chloride concentration ([Cl–
]i) at levels above electrochemical equilibrium. Two different genes (Slc12a1 and
Slc12a2) encode for two isoforms of the transporter, named NKCC1 and NKCC2.
NKCC1 is a ubiquitously distributed protein whereas NKCC2 is expressed exclusively in
the apical membrane of the thick ascending portion of the Henle's loop where it plays a
key role in NaCl and water absorption. NKCC transport activity is inhibited by loopdiuretics such as bumetanide and furosemide, drugs that are used for the treatment of
edema associated with congestive heart failure. In spite of the very well known
pharmacological effects of loop-diuretics of NKCC function, relatively nothing is known
regarding the impact of these drugs on NKCC1 gene expression. We screened several cell
lines suitable for gene expression studies and found that COS-7, a kidney fibroblast-like
cell line expresses NKCC1 at the functional and molecular levels. NKCC1 expression
was ascertained by Western bolt, immunofluorescence and reverse transcription (RT)
coupled to the polymerase chain reaction (PCR). Our results show that NKCC1 is
expressed as a protein of ~170 kDa. Under basal conditions NKCC1 is mainly localized
in the perinuclear region as well as in small intracellular compartments whereas a small
fraction is localized near or at the plasma membrane. Upon chronic treatment with loopdiuretics, COS-7 cells shrunk, as expected. This finding correlated with down regulation
of NKCC1 protein expression and re-localization/retention/concentration of NKCC1 in
the perinuclear region in structures resembling the Golgi apparatus. We conclude that
loop-diuretics regulate NKCC1 protein expression and localization in COS-7 cells.
Poster presented in Ohio Physiological Society (OPS), 2011, University of Cincinnati,
Cincinnati, OH.

82

APPENDIX B
Short-hairpin RNA-mediated silencing of NKCC1 in COS7 cells and its effect on cell
volume
Saeed Alshahrani & Mauricio Di Fulvio.
Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright
State University, Dayton, OH

Na+K+2Cl– cotransporters (NKCCs) effect the electroneutral movement of Na+, K+ and
2Cl– ions across the plasma membrane. Under physiological conditions NKCCs function
as active, Na+-dependent, Cl– uptake transporters. Two NKCC isoforms, encoded by two
different genes have been identified: NKCC1 and NKCC2. NKCC1 is a ubiquitously
expressed gene whereas NKCC2 is considered to be exclusive of the kidney. We describe
for the first time a viable knock-down strategy to silence endogenous NKCC1 expression
in a widely used, easy to transfect cell line. NKCC1 mRNA expression in COS7 cells
was eliminated transfecting these cells with a poly-cistronic vector encoding for GFP and
an shRNA directed against the third exon of human NKCC1. Stable transfectants were
selected by continuous incubation in the presence of puromycin. Cells stably expressing
GFP and resistant to the drug were selected and cloned. NKCC1 expression was followed
by Western bolt, immunofluorescence and reverse transcription (RT) coupled to the
polymerase chain reaction (PCR). The impact of NKCC1 depletion on cell volume was
followed morphometrically. We found that cells lacking NKCC1 are shrunken suggesting
that NKCC1 is the sole regulator of cell volume in these cells. This new cell system will
open the possibility to study the functional, pharmacological and molecular properties of
candidate genes involved in volume regulation.

Poster presented at the Experimental Biology (EB) meeting 2012; San Diego, CA.
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APPENDIX C
Insulin secretion in mice deficient in the Slc12a2 gene
Saeed Alshahrani & Mauricio Di Fulvio.
Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright
State University, Dayton, OH
Insulin secretion from pancreatic β-cells is a complex process involving the integration
and interaction of multiple external and internal stimuli. The most well known
mechanism whereby glucose induces insulin secretion involves the ATP-dependent K+channel pathway. Glucose metabolism within the β-cell increases the ATP/ADP ratio
closing K+-channels and thus depolarizing the plasma membrane. This activates voltagedependent Ca2+-channels inducing Ca2+ influx and triggering insulin secretion from
stored granules. However, in addition to this cationic pathway, glucose also stimulates
Cl– efflux. This contributes to β-cell's electrical and secretory activities. The electrogenic
efflux of Cl– in response to glucose is possible because β-cells maintain the intracellular
chloride concentration ([Cl–]i) above electrochemical equilibrium due to the functional
presence in these cells of the Na+K+2Cl– co-transporter, a protein encoded by the Slc12a2
gene. This co-transporter is the target of loop-diuretics such as bumetanide or furosemide.
Accordingly, these drugs are known to impair insulin secretion in response to glucose.
However, our results show that glucose-induced insulin secretion is far from being
impaired in mice carrying heterozygous or homozygous inactivation of the Slc12a2 gene.
Transgenic mice lacking one or both functional alleles of this gene have better fasting
glycaemia and improved glucose tolerance when compared to WT. Further, mice
deficient in the Slc12a2 gene are more sensitive to glucose when compared to WT
littermates whereas overall insulin sensitivity is maintained in these mice, regardless of
genotype. Together, or results suggest for the first time that i) the Slc12a2 gene is not
required for glucose-induced insulin secretion, ii) additional mechanisms are involved in
regulating [Cl–]i in β-cells and, iii) hemiexpression of the Slc12a2 gene in these mice may
have a positive impact in glucose homeostasis.
Poster accepted for presentation at the Endocrine Society's Annual Meeting 2012
(ENDO2012); Houston, TX.
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APPENDIX D
Rattus norvegicus cell-line INS-1E solute carrier family 12
member 1 (Slc12a1) mRNA, complete cds
GenBank: JN579707.1
LOCUS
JN579707
4595 bp
mRNA
linear
ROD 06-NOV-2011
DEFINITION Rattus norvegicus cell-line INS-1E solute carrier
family 12 member 1 (Slc12a1) mRNA, complete cds.
ACCESSION
JN579707
VERSION
JN579707.1 GI:354992502
KEYWORDS
SOURCE
Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata;
Vertebrata; Euteleostomi; Mammalia; Eutheria;
Euarchontoglires; Glires; Rodentia;
Sciurognathi; Muroidea; Muridae; Murinae;
Rattus.
REFERENCE
1 (bases 1 to 4595)
AUTHORS
Alshahrani,S. and Di Fulvio,M.
TITLE
Expression of the slc12a1 gene in pancreatic
ß-cells: Molecular characterization and in
silico analysis.
JOURNAL
Cell Physiol Biochem 30:95-112
REFERENCE
2 (bases 1 to 4595)
AUTHORS
Alshahrani,S. and Di Fulvio,M.
TITLE
Direct Submission
JOURNAL
Submitted (12-AUG-2011) Pharmacology &
Toxicology, Wright State
University - BSOM, 3640 Colonel Glenn Hwy 216
Health Sciences Bldg,
Dayton, OH 45435, USA
FEATURES
source

gene
CDS

Location/Qualifiers
1..4595
/organism="Rattus norvegicus"
/mol_type="mRNA"
/db_xref="taxon:10116"
/cell_line="INS-1E"
1..4595
/gene="Slc12a1"
/gene_synonym="Nkcc2"
216..3503
/gene="Slc12a1"
/gene_synonym="Nkcc2"
/note="Na/K/2Cl co-transporter variant 2 isoform A;
rNKCC2A"
/codon_start=1
/product="solute carrier family 12 member 1"
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/protein_id="AER46075.1"
/db_xref="GI:354992503"
/translation="MSVNIPSNSVPSGASRFQVHVINEGHGSGAAMSDSTDPPHYEET
SFGDEAQNRLKISFRPGNQECYENFLQTGETAKTDTTFHAYDSHTNTYYLQTFGHNTM
DAVPKIEYYRNTGSVSGPKVNRPSLQEIHEQLAKNVAVAPGSADRVANGDGMPGDEQT
ENKEEDVTGVVKFGWVKGVLVRCMLNIWGVMLFIRLSWIVGEAGIGLGVLIILLSTMV
TSITGLSTSAIATNGFVRGGGAYYLISRSLGPEFGGSIGLIFAFANAVAVAMYVVGFA
ETVVDLLKESDSMMVDPTNDIRIIGSITVVILLGISVAGMEWEAKAQVILLVILLIAI
ANFFIGTVIPSNNEKKSRGFFNYQASIFAENFGPRFTKGEGFFSVFAIFFPAATGILA
GANISGDLEDPQDAIPRGTMLAIFITTVAYIGVAICVAACVVRDATGSMNDTVVSGMN
CNGSAACGLGYDFSRCQHEPCQYGLMNNFQVMSMVSGFGPLITAGIFSATLSSALASL
VSAPKVFQALCKDNIFKGLQFFAKGYGKNNEPLRGYFLTFVIAMAFILIAELNVIAPI
ISNFFLASYALINFSCFHASYAKSPGWRPAYGIYNMWVSLFGAILCCAVMFVINWWAA
VITYVIELFLYIYVTYKKPDVNWGSSTQALSYVSALDNALELTTVEDHVKNFRPQCIV
LTGGPMTRPALLDITHAFTKNSGLCICCEVFVGPRKLCVKEMNSGMAKKQAWLMKNKI
KAFYAAVAADCFRDGVRSLLQASGLGRMKPNTLVIGYKKNWRKAPLSELENYVGIIHD
AFDFEIGVVIVRISQGFDISPVLQVQDELEKLEQERLALEAAIKDNDCEEGKGGIRGL
FKKAGKLNITKPAPKKDSNISTIQSMHVGEFNQKLVEASAQFKKKQGKGTIDVWWLFD
DGGLTLLIPYILTLRKKWKDCKLRIYVGGKINRIEEEKISMASLLSKFRIKFADIHII
GDINIKPNKESWKVFEEMIEPYRLHESHKDLTTAEKLKRESPWKITDAELEAVKEKSY
RQVRLNELLQEHSRAANLIVLSLPVARKGSISDLLYMAWLEILTKNLPPVLLVRGNHK
NVLTFYS"

ORIGIN
1
61
121
181
241
301
361
421
481
541
601
661
721
781
841
901
961
1021
1081
1141
1201
1261
1321
1381
1441
1501
1561
1621
1681
1741
1801
1861
1921
1981
2041
2101
2161
2221
2281
2341
2401
2461
2521
2581
2641
2701
2761

cagaaggcgg
acatatcaac
tcggtattgt
ctgtaaaata
cagtgcccag
gtgcagccat
aagcccaaaa
ttctccaaac
caaacacata
agtactaccg
agatccacga
ctaatggaga
gtgttgtgaa
gagtcatgct
ttctcataat
tagcaactaa
ggcccgagtt
ctatgtatgt
tgatggtgga
taggaatttc
ttcttctaat
aaaagtccag
gcttcacaaa
ggattcttgc
gagggaccat
tagctgcctg
tgaattgcaa
agccatgcca
gccccctcat
tcagtgcacc
tcttcgcaaa
tgatagccat
acttcttcct
aatcgccagg
ccattttgtg
tcattgagct
cctccacaca
tggaagacca
caagacctgc
gctgcgaagt
ctaaaaagca
cagactgctt
agccaaacac
ttgagaatta
tcagaatcag
aactggaaca
gcaagggggg

ctgaatggga
attacagcag
aaccctacga
ggtagttcaa
tggtgccagt
gagtgacagc
cagactgaaa
tggagagact
ttacctacaa
caacaccggc
gcagctagct
tgggatgcct
gtttggatgg
cttcattcgc
tcttctttcc
cgggtttgtt
cggtgggtca
ggtgggattt
tccaaccaat
agtagctgga
tgctattgca
aggtttcttt
gggtgaaggc
tggtgccaat
gctggccatt
tgtggtccga
tgggtccgca
gtatgggttg
caccgcaggg
caaagtattc
gggctatggg
ggcattcatt
ggcctcatat
atggaggccg
ctgtgcagtc
cttcctctat
ggctctgtcc
tgtgaaaaac
tctcctggac
cttcgtggga
ggcctggctg
cagggacggt
tctagtgatt
cgtgggaatc
ccaagggttt
ggagagactg
catccgaggc

ggcagctttg
gaatccagct
ttctctattt
agtagatttt
cgtttccaag
acggaccccc
atcagcttta
gctaaaacag
acctttggcc
agtgtgagcg
aagaatgtgg
ggagatgagc
gtgaaaggtg
ctctcctgga
accatggtaa
cgtggaggtg
ataggcctga
gctgagactg
gacatccgga
atggaatggg
aacttcttca
aattaccaag
ttcttctctg
atctcaggag
ttcatcacca
gacgccactg
gcctgcggac
atgaacaatt
atcttttcgg
caggctctgt
aaaaacaacg
ctcatcgccg
gcgcttatta
gcatatggga
atgtttgtca
atctatgtga
tacgtgagcg
ttcagacccc
ataacccatg
cctcgcaagt
atgaagaaca
gtgcggagtc
ggatacaaaa
atacatgacg
gacatctctc
gctctggagg
ttgtttaaga

ggaatcattc
atcgggtcgt
tgaagcagaa
ggaagatgtc
tccatgttat
cacattatga
ggcctgggaa
acaccacgtt
acaacaccat
ggcccaaggt
ctgtggctcc
aaacagaaaa
tgctggtgag
ttgtaggaga
cttctattac
gggcctacta
tctttgcttt
tagtagatct
ttataggctc
aggcaaaggc
ttggaactgt
catcaatatt
tctttgccat
atttggagga
ccgtcgccta
ggagcatgaa
tgggctacga
ttcaggtcat
caacactgtc
gcaaggacaa
agcccctgag
agctgaacgt
atttctcctg
tttacaacat
tcaactggtg
cttataagaa
ctttagacaa
agtgcattgt
cctttacgaa
tgtgtgttaa
aaatcaaggc
tccttcaggc
agaactggag
cctttgactt
cagttctcca
ccgcaatcaa
aggccggcaa
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tgaagattac
ctagatccaa
gtaggttaaa
agtcaacatc
aaatgagggc
agagacctct
tcaggagtgc
tcacgcctat
ggacgccgtc
caaccggccg
tggttcagct
caaggaagaa
gtgcatgctg
agcgggaatt
tgggttgtca
tcttatttcc
tgctaatgca
tcttaaggag
catcacagtg
ccaagtcatt
cattccatcc
tgcagaaaac
ttttttccca
tccccaagat
cataggtgtt
cgacactgtc
cttctcaaga
gagcatggtg
ttcggcccta
catcttcaaa
agggtacttc
cattgcacct
cttccatgcc
gtgggtatct
ggcggctgtc
gccagatgtg
tgctctggaa
cttaacagga
gaatagtggc
agagatgaac
tttttatgct
ctcaggcctg
gaaagctccc
tgagattggt
ggtacaagat
agacaacgac
actgaacatt

atgggagacc
aaccaagtgc
acaccaacca
ccttccaact
catggcagtg
ttcggggatg
tatgaaaatt
gactctcaca
cccaagattg
agcctgcagg
gacagggttg
gacgtgactg
aacatctggg
ggtcttggag
acttctgcga
agaagtttag
gtggctgttg
agtgattcga
gtgattcttc
cttctggtca
aacaatgaga
tttgggccac
gcagctactg
gccatcccca
gctatttgcg
gtttctggga
tgtcagcatg
tccgggttcg
gcctccctcg
ggacttcagt
ctcacttttg
atcatatcca
tcgtatgcca
ctcttcggag
atcacctatg
aactggggct
ttaaccacag
ggacccatga
ctctgtatct
agtggcatgg
gcggtggcgg
gggagaatga
ttgtctgagc
gtagtcatag
gaactggaga
tgtgaggagg
accaagccgg

2821
2881
2941
3001
3061
3121
3181
3241
3301
3361
3421
3481
3541
3601
3661
3721
3781
3841
3901
3961
4021
4081
4141
4201
4261
4321
4381
4441
4501
4561

cccctaaaaa
agaagctggt
tttggtggtt
gaaagaaatg
aagaggaaaa
ttcatataat
agatgattga
taaaaagaga
gttaccgcca
tcgtattgag
ggttagaaat
atgtcctgac
aataattaca
cctctggaga
ttaatgagag
ggtgaataag
tgagctccag
gccacaggcc
aggcggctat
agaagtttgt
aaagtgttca
acctctgatc
aaagacacat
ctggttaaat
tggtttgcat
caatccacta
atatgggttt
aggtgttgat
atatgataaa
gtggggggca

agacagcaac
agaagccagc
atttgatgat
gaaagactgt
aatttcaatg
tggagacatc
accttatagg
aagtccatgg
agttcgactg
ccttccagtg
cctgaccaag
attttactct
aaacgtgtct
ctatcccacc
ttttttccca
aaattaataa
gcaaacgcaa
cacagcgggc
catagggaaa
ggagatttaa
aagcagttac
acacgtagct
gttccactta
gttttgaaat
agacgaaata
ctaaaaatat
tatagaataa
ttttcttctt
tggcttggtt
aatcaacctg

atcagcacca
gctcagttta
ggagggttga
aagttaagaa
gcttctcttc
aacattaagc
ctccacgaaa
aaaattacag
aacgagctgt
gcgagaaaag
aacctccctc
taaagcgcga
ggtactttgt
tgattctaca
ccagttttaa
gagctggctg
tctcttgttt
tctctttaag
gacacactgg
aaatcaatat
ctaaattaag
tgcatttgct
gacgaaatag
ttctacctta
aaaatagacg
atccagatcc
caaggatata
gttcatgtgt
ttggttttgt
aaataaaatt

tccagtcgat
aaaagaaaca
cactgcttat
tctatgttgg
tcagcaaatt
caaacaaaga
gccacaaaga
atgcagaact
tacaggagca
gatctatttc
ctgtgctact
gggatgagaa
gttttaaaac
taaatttcat
aaacatcgaa
acatgcttgc
ccgtggattc
ttgttattga
gtcagtggcc
ccggaaactg
gtttatttaa
gctagccaga
agtcccaaca
atactacttt
atctcattga
tacatttatt
agtggagaaa
gtataatatt
tggcatattt
ctact

//
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gcacgtcggg
gggaaaaggc
cccatatatc
aggaaaaatc
taggataaaa
gagctggaaa
tttgaccact
ggaagcagtc
ttccagagcc
ggatttgttg
ggttagagga
atgttgtacc
ctcatctatg
cttttttaaa
aacatttttc
aggatgtgct
tgctgcatgg
cagactggtg
tgattctgct
taagaaggac
tgcagccgat
ggtacactag
tacaaatatc
atcttttttc
aaaataatct
tactttctct
cttgtaaaat
taatcacaga
tgactgttct

gagttcaatc
acgatcgatg
ttgactctca
aaccgcattg
tttgcagaca
gtctttgaag
gctgagaaat
aaggaaaaga
gccaacctca
tacatggcgt
aatcacaaga
ttggtgtccg
aatatacaaa
aaagttatta
ccttgtcgct
aatgtagatg
ccccgtgcag
tggtgaaagc
tggcctcctg
tagagtctac
aataagctta
gtaggtgagc
aattgtcttc
tctgattaag
cacaggtttc
atatacaggt
tttaaaacac
aaaaatgctt
ggggaagctt
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